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Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a common and preventable 
chronic disease which is characterized by airflow limitation that is usually 
progressive (1). An estimated 299 million people worldwide suffered from the 
disease in 2017 (2) and it caused 3 million deaths in 2016, making it the third 
most common cause of death worldwide (3). Tobacco smoking and exposure to 
air pollution, toxic gases and biomass fuel emission are the most common risk 
factors for developing COPD (4).
The pathophysiology in the lungs primarily consists of chronic bronchitis (airway 
inflammation) and emphysema (destruction of the small airways) (1), but COPD 
is highly heterogeneous. Various systemic manifestations outside the lungs and 
airways are common. These include cardiovascular disease (5), musculoskeletal 
impairment (6), cachexia (7), sarcopenia (8), metabolic syndrome (MetS) (9), 
anxiety and depression (10, 11) and cognitive abnormalities (e.g., 12, 13). The entire 
constellation of COPD manifestations contributes to increased disease burden, 
worsened health status and functional performance, increased hospitalization and 
mortality risk and higher healthcare costs (14-16).
COPD is incurable but can be treated. Smoking cessation is the most effective 
prevention as well as treatment strategy. The current guidelines recommend 
additional pharmacological treatment using a combination of long-acting 
muscarinic antagonists and b2-agonists, combined in severe cases with inhaled 
corticosteroids (1). Patients who remain symptomatic despite optimal treatment 
and/or those with complex pathology (such as poor lung function, high burden of 
comorbidities, a poor functional or nutritional status and/or frequent exacerbations) 
can be referred to pulmonary rehabilitation (PR) (17) or in very specific cases be 
eligible for lung volume-reducing endoscopic or surgical intervention (1).
Pulmonary rehabilitation
PR is defined as "a comprehensive intervention based on a thorough patient 
assessment followed by patient-tailored therapies that include, but are not limited 
to, exercise training, education and behavior change, designed to improve the 
physical and psychological condition of people with chronic respiratory disease 
and to promote the long-term adherence to health-enhancing behaviors" (17).
PR is one of the most effective interventions to improve the health status of 




increase significantly over the course of a PR program (18). However, the long-
term efficacy of PR has not been investigated yet. This is relevant because PR-
induced gains translate only poorly into a healthier lifestyle, such as more physical 
activity, after PR (18). Moreover, specific subgroups of patients could benefit 
from specific additional treatments, such as nutritional supplementation (19, 20). 
These considerations were the main rationale to design the randomized, double-
blind, placebo-controlled NUTRAIN trial. This trial investigated the efficacy and 
cost-effectiveness of a multimodal nutritional management strategy, consisting 
of nutritional supplementation and dietary counseling, in COPD patients with 
low muscle mass during a 4-month outpatient PR program and in the 8-month 
maintenance phase thereafter. The results of the initial 4-month phase were 
published earlier (21); the efficacy and cost-effectiveness of the overall strategy 
are reported in Chapter 2 of this thesis.
Nutritional supplementation did not improve quadriceps muscle strength during 
the initial PR phase of the NUTRAIN trial. Interestingly, however, supplementation 
prevented declines in daily physical activity (21). This dissociation between physical 
capacity and activity, combined with positive effects on plasma micronutrient status 
and quality of life (21) led to the hypothesis that mechanisms affecting cognitive 
performance and mental health might be involved.
The main aim of this thesis was therefore to investigate determinants of cognitive 
performance in patients with COPD and the potential efficacy of working memory 
training (WMT) next to motivational regulations in increasing patients' adherence 
to a healthy lifestyle.
Motivational regulations as determinants of PR-induced health 
improvement
The central tenet of self-determination theory (SDT) is that motivation is the key 
determinant of behavior (22). SDT conceptualizes motivation as a quantitative 
construct (i.e., one can be more or less motivated towards something), but it 
also distinguishes six qualitatively different motivational regulations which can 
differentially drive behavior. These regulations can be placed on a continuum, 
ranging from being more intrinsic (performing a behavior because of the 
enjoyment derived from doing it) to more extrinsic forms of motivation (performing 
a behavior because of some secondary rewards associated with it) (23). Although 
all motivational regulations can drive behavior, a larger reliance on more intrinsic 




Intrinsic behavioral regulation is more stable and enduring and benefits one's 
wellbeing more compared to controlled regulation (24).
Because of their important role in determining behavior, motivational regulations 
could be the key to ensure PR-induced gains translate into a longer-term healthy 
lifestyle after the PR program is completed and the associated external support 
is not present anymore. If motivational regulations are related to healthy lifestyle 
behaviors before, during and/or after a PR program, they could be used as 
predictors of adherence to healthy lifestyle behaviors, or even as interventional 
targets to improve this adherence. Earlier studies have already shown that 
motivational interviewing, which is a psychological counseling technique based 
on SDT, can increase medication adherence (25, 26), exercise compliance (26) and 
health-related quality of life (26-28) and can reduce hospitalization rates (26, 27) 
in patients with COPD.
Chapter 3 investigates the value of motivational regulations to predict the carry-
over of PR-induced healthy lifestyle gains into a healthier lifestyle.
Cognitive functioning
Cognitive functioning involves any brain function required for perceiving, 
registering, storing, retrieving and using information from the environment 
in order to be able to adapt one's behavior to novel situations (29). Cognitive 
functioning is not a unitary construct but consists of different functions, such 
as memory, attention, self-control, task switching, inhibition and many more. 
Furthermore, 'lower' functions can be distinguished from 'higher' ones, with the 
lower functions (e.g., sensory processing, attention and language abilities) serving 
as the foundation for the higher ones (e.g., cognitive flexibility, self-control and 
problem-solving) (29).
Executive functions encompass various higher-order cognitive functions involved 
in behavioral control. Specifically, inhibition, task switching and working memory 
(WM) are generally considered to jointly constitute executive functioning (30). 
Inhibition refers to the ability to override or interrupt undesired behavioral 
responses (31), and enables to focus on one particular thing instead of being 
distracted by other items in our environment. Task switching is the ability to 
quickly switch one's focus from one item to another, and to change demands and 
priorities (30). This ability makes it possible to avoid behavioral interference from 
previous tasks, thereby preventing perseveration when a behavioral strategy does 




to temporarily keep important information in mind, enabling the information to 
be mentally manipulated (33). WM is also involved in the ability to focus one's 
attention (34) and to actively keep a representation of long-term goals (35).
There are large inter-individual differences in cognitive functioning. One person's 
WM might be very strong (for instance if he or she is able to remember and 
immediately reproduce an entire phone number after hearing it once), whereas 
in someone else it might be very poor. Likewise, there are large intra-individual 
differences in cognitive functioning. Someone might simultaneously have a very 
strong long-term memory but very poor inhibition skills.
Measuring cognitive performance
Cognitive performance can be quantified by using standardized cognitive tests. 
Because so many different cognitive domains exist, countless tests have been 
developed to gauge people's performance on those domains. Cognitive tests 
can be distinguished into screening tools and comprehensive neuropsychological 
assessment batteries (36).
Screening tools, such as the Mini-Mental State Examination (MMSE) (37), the 
Montreal Cognitive Assessment (MoCA) (38) and the Addenbrooke's Cognitive 
Examination-Revised (ACE-R) (39), can be administered relatively quickly (often 
within 10 to 15 minutes), are generally narrow in scope, and they do not have a 
diagnostic purpose (36). Screening tools are used in clinical practice to obtain a 
quick overview of the cognitive performance of a person presenting with memory 
problems and to determine whether he or she can benefit from referral for more 
extensive cognitive assessment.
More detailed assessment is conducted using comprehensive neuropsychological 
test batteries (36), such as the Cambridge Neuropsychological Test Automated 
Battery (CANTAB). It takes more time and effort to administer such batteries, 
but their broader scope (i.e., their ability to measure more cognitive domains 
more thoroughly) and their higher sensitivity to detect CI are large advantages 
compared to screening tools (36). Therefore, such batteries can be used for 
diagnostic purposes in a clinical setting (36) and as valid and reliable outcome 
measures for clinical trials in a scientific setting (40).
Cognitive impairment in COPD and its consequences
The large impact of COPD on the brain and cognitive functioning has long been 




of COPD has increased in recent years (e.g., 12, 13). The prevalence of CI is 
significantly higher in patients with COPD compared to non-COPD controls. A 
recent large review reported a 32% prevalence of any CI and a 25% prevalence 
of mild CI (MCI) in patients with COPD (41). More recently, a 39.4% prevalence 
of CI was reported in clinically stable patients (42), and a 41.5% (43) and 56.7% 
(13) prevalence in patients referred to PR. In contrast, the prevalence of CI among 
non-COPD controls in the latter study was 13.3%. In another study in a PR context, 
9.5% of patients with COPD scored below the 5th percentile of a normal reference 
group on the MoCA, and only 38.1% of patients scored higher than the median of 
the reference group (44).
The consequences of CI extend beyond the cognitive domain. CI affects self-
management skills, which are especially relevant in patients with chronic diseases. 
Cognitive functioning is related to the accuracy of recalling severity of fatigue and 
dyspnea over a two-week period (45) and to inhaler competency (46) in patients 
with COPD. Impaired prospective memory and planning can lead to decreased 
treatment and medication adherence (47). The risks of hospitalization and 
mortality (48) are higher in patients with CI compared to those without. Cognitive 
functioning is also related to engagement in unhealthy lifestyle behaviors, such 
as food intake in overweight people (49) and alcohol consumption in problem 
drinkers (50). The relationship between CI and health-related quality of life remains 
unclear: in some studies the two were significantly negatively related (42, 51, 52) 
but not in others (43, 53).
Cognitive stress susceptibility is already heightened by chronic disease (54), 
and CI and cerebral abnormalities might further amplify these effects: executive 
functioning is related to cognitive stress reactivity (55) and perception (56), and the 
prefrontal cortex and hippocampus are smaller in patients with COPD compared 
to healthy controls (57-59). These are the two main areas involved in the regulation 
of the hypothalamic-pituitary-adrenal (HPA) axis, which is activated in response to 
stress (60, 61). Moreover, exposure to cortisol, which is the end-product of HPA axis 
activation, contributes to shrinkage of these two areas (62-64), thereby creating a 
vicious cycle of progressively poorer stress regulation.
Potential etiological factors
Many typical or common factors associated with COPD are independently related 
to poorer cognitive functioning. All of these likely contribute to CI in COPD, 
depending on the extent to which they affect any given patient. Disease-specific 
factors include inflammation (65, 66), exacerbations (51, 67, 68), hypoxemia and 




and depression (73) are common comorbidities of COPD. In addition, modifiable 
lifestyle factors exhibited by many patients with COPD, such as a history of smoking 
(74), physical inactivity (75-77) and a low-quality diet (78) play a role. Chapter 
4 of this dissertation reviews the initial knowledge base around the specific 
cognitive domains which are predominantly affected in COPD, the prevalence and 
pathophysiology of CI in COPD and the impact of CI on health, self-management 
and daily life outcomes.
Metabolic abnormalities, such as MetS and sarcopenia, are more common in 
COPD compared to non-COPD controls (8, 9), and both are independently related 
to poorer cognitive performance (79-83). It is still unknown, however, whether 
MetS and sarcopenia amplify the detrimental impact of COPD on cognitive 
performance. If MetS and sarcopenia are related to CI in COPD, they could 
constitute prognostic and potential screening factors for the development of CI 
and/or interventional targets to prevent or counteract its development. Therefore, 
Chapter 5 investigates in patients with COPD referred for PR whether cognitive 
performance is poorer in patients with MetS or sarcopenia compared to those 
without.
Treating cognitive impairment in COPD
The large impact of CI on the disease management, health outcomes, lifestyle 
behaviors and cognitive stress susceptibility of patients with COPD emphasizes 
the importance to treat CI. Cognitive performance is trainable: the brain is plastic 
(84, 85). Cognitive performance can therefore be improved through repeated 
practice. One earlier study investigated the effects of cognitive training in patients 
with COPD, which did not find improved cognitive performance (86). However, 
this intervention had a relatively low training load and was aimed at improving 
attention and logical-deductive thinking. In contrast, WM training (WMT) would 
be especially promising in COPD, because WM is the principal cognitive domain 
underlying both general cognitive performance (87) and top-down behavioral 
regulation.
The connection between WM and general cognitive performance implies that the 
likelihood of training-induced cognitive improvement 'spilling over' into other 
cognitive domains is largest when WM is trained, as opposed to other cognitive 
domains. This 'spill-over' is known in the neuropsychological literature as 'transfer' 
(88). Most cognitive or WM training interventions are aimed at children or 




Studies that specifically investigate WMT in healthy elderly populations yield mixed 
results (90-92), but WMT has never been administered to patients with COPD yet.
The connection between WM and top-down behavioral control is explained 
by dual-process theories of cognitive functioning (93-95). These postulate the 
existence of two cognitive processing systems: a fast system and a slower one (95, 
96). The fast system is responsible for executing relatively easy, well-known and/
or highly automated cognitive processes; the slow system for more deliberate, 
controlled and conscious execution of harder cognitive tasks (96). WM underlies 
the latter system (97), which is responsible for top-down behavioral control. 
Strengthening it would make it easier to execute controlled responses compared 
to less opportune automatic ones. Several studies have confirmed that cognitive 
training can decrease engagement in unhealthy lifestyle behaviors, such as 
overeating in obese people (49) and consuming alcohol in problem drinkers 
(50), but the effects of cognitive training or WMT on adherence to healthy lifestyle 
behaviors such as a healthy diet or physical activity (PA) have remained under-
Investigated. This is relevant in COPD because a sedentary lifestyle is common 
in advanced stages of COPD (98-100), as is a poor dietary quality. In 564 patients 
referred for PR, protein intake deviated from the recommended daily intake in 
30% of patients, carbohydrate intake in 26% and dietary fat intake in almost one 
third (101). Intake of many micronutrients, such as iron, sodium, zinc, niacin, folic 
acid (102), vitamin B6, B9 and B12, b-carotene (103), vitamins A, C, D (101) and E 
(101, 103) was low. 
Chapter 6 therefore presents the results of the randomized, placebo-controlled 
Cogtrain trial, investigating whether a 12-week home-based WMT program 
followed by a 12-week maintenance program could establish and maintain 
improvement in cognitive performance, physical capacity and activity, dietary 
quality, cognitive stress susceptibility and perception, recall of prespecified 
healthy lifestyle goals, healthy lifestyle motivation and psychological wellbeing in 
patients with COPD.
The results of the current thesis will be discussed and placed in a broader context 
in Chapter 7, with a particular focus on cognitive functioning in COPD and on the 
potential efficacy of WMT and other promising interventions to improve cognitive 
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Background and aims: The efficacy of nutritional intervention to enhance short- 
and long-term outcomes of pulmonary rehabilitation in COPD is still unclear, 
hence this paper aims to investigate the clinical outcome and cost-effectiveness 
of a 12-month nutritional intervention strategy in muscle-wasted COPD patients.
Methods: Prior to a 4-month pulmonary rehabilitation programme, 81 muscle-
wasted COPD patients (51% males, aged 62.5±0.9 years) with moderate 
airflow obstruction (FEV1 55.1±2.2% predicted) and impaired exercise capacity 
(Wmax 63.5±2.4% predicted) were randomized to 3 portions of nutritional 
supplementation per day (enriched with leucine, vitamin D and polyunsaturated 
fatty acids) [NUTRITION] or PLACEBO (phase 1). In the unblinded 8-month 
maintenance phase (phase 2), both groups received structured feedback on their 
physical activity level assessed by accelerometry. NUTRITION additionally received 
1 portion of supplemental nutrition per day and motivational interviewing-based 
nutritional counselling. A 3-month follow-up (phase 3) was included.
Results: After 12 months, physical capacity measured by quadriceps muscle 
strength and cycle endurance time were not different, but physical activity was 
higher in NUTRITION than in PLACEBO (D 1030 steps/day, p=0.025). Plasma levels 
of the enriched nutrients (p<0.001) were higher in NUTRITION than PLACEBO. 
Trends towards weight gain in NUTRITION and weight loss in PLACEBO led to a 
significant between-group difference after 12 months (D 1.54 kg, p=0.041). The 
HADS anxiety and depression scores improved in NUTRITION only (D -1.92 points, 
p=0.037). Generic quality of life (EQ-5D) was decreased in PLACEBO but not in 
NUTRITION (between-group difference after 15 months 0.072 points, p=0.009). 
Overall motivation towards exercising and healthy eating was high and did not 
change significantly after 12 months; only amotivation towards healthy eating 
yielded a significant between-group difference (D 1.022 points, p=0.015). The cost 
per quality-adjusted life-year after 15 months was €16,750.
Conclusions: Nutritional intervention in muscle-wasted patients with moderate 
COPD does not enhance long-term outcome of exercise training on physical 
capacity but ameliorates plasma levels of the supplemented nutrients, total body 
weight, physical activity and generic health status, at an acceptable increase of 
costs for patients with high disease burden.




Extra-pulmonary pathology enhances disease burden in patients with chronic 
obstructive pulmonary disease (COPD) (1). Decreased muscle mass is associated 
with increased prevalence of osteoporosis, lower muscle strength and exercise 
performance, and increased mortality risk (2). Furthermore, COPD is characterized 
by impaired muscle oxidative metabolism, which cannot simply be explained by 
disuse alone (3, 4) and may predominate in patients with low muscle mass (5).
Exercise training is a cornerstone of pulmonary rehabilitation (PR) (6), and improves 
lower limb muscle strength, exercise performance, and in some studies also daily 
physical activity level (7, 8). Protein and specific nutrient supplementation could 
potentiate the effects of PR or represent an alternative to exercise training in 
severely deconditioned patients. In contrast to other nutrients including creatine 
and nitrate (9), to date only polyunsaturated fatty acids (PUFA) (10) and vitamin D 
(11) have been effective as single-nutrient add-on treatment in COPD by enhancing 
inspiratory muscle strength (11) and maximal oxygen uptake (10, 11) during PR 
which could be via immune modulation and/or boosting oxidative metabolism. 
Multimodal nutritional interventions are interesting to explore because the 
regulation of muscle mass and metabolism is controlled by multiple tightly 
intertwined pathways (12). In the NUTRAIN trial (13), we developed a multimodal 
stepwise nutritional intervention approach including high-quality protein enriched 
with leucine, vitamin D, and omega-3 PUFA, based on evidence regarding the 
mode of action of these nutrients on skeletal muscle maintenance, combined with 
reported deficiencies in COPD. The nutritional supplementation was supplemented 
by nutritional counselling. This approach was investigated in COPD patients with 
low muscle mass as a susceptible group for accelerated functional decline (14). 
The results of the first phase, which took place during PR, have been reported 
earlier (13). During this phase nutritional supplementation improved nutritional 
status but did not enhance lower limb muscle strength or muscle mass regain. A 
remarkable between-group difference was shown in physical activity level, largely 
due to a decline in the PLACEBO group only, whereas the NUTRITION group 
remained stable, indicating that this nutritional strategy might be effective to 
attenuate the decline in physical activity typically observed in patients with COPD 
(15). Exercise-induced muscle fatigue is a commonly reported symptom in COPD 
(16), and nutritional modulation thereof or nutritional effects beyond the muscle 
(i.e., the brain or cardiovascular system) (17, 18) might explain this observation. 
Accordingly, Calder et al. (19) showed in a 3-month randomized controlled trial 




vitamin D, reduced walking exercise-induced fatigue (measured using the Borg 
scale) in COPD patients with low muscle mass.
We hypothesized that improved nutritional status and positive effects on daily 
physical activity level might also enhance the long-term efficacy of the intervention 
with quadriceps muscle strength (QMS) as primary outcome. The current paper 
aims to investigate the clinical outcome of the overall nutritional management 
strategy of the NUTRAIN trial, including phase 1, the 8-month maintenance phase 
after completion of PR (phase 2) and the 3-month follow-up (phase 3). Furthermore, 
the cost-effectiveness of the intervention after 15 months is explored.
Methods 
Study design
The trial was integrated in the outpatient PR program of 7 hospitals in The 
Netherlands (Sint Anna hospital in Geldrop, Maxima Medical Centre in Veldhoven 
[until March 2013], Laurentius hospital in Roermond, Sint Jans Gasthuis hospital 
in Weert, Elkerliek hospital in Helmond, Maastricht University Medical Centre and 
Catharina hospital in Eindhoven), supervised by CIRO, a center of expertise for 
patients with chronic organ failure in Horn. Participants were recruited during the 
assessment period at CIRO when eligible for outpatient PR at one of the hospitals. 
Patients with severe COPD referred for inpatient PR at CIRO were not included. 
Every participant underwent an interview with a chest physician at admission; 
the study physician checked eligibility of potential participants during this visit 
and asked participants whether they could be contacted by the researcher. The 
study was registered at clinicaltrials.gov (NCT01344135) and the medical ethics 
committee of Maastricht University Medical Centre granted ethical approval 
(NL34927068.10/MEC 11-3-004). All participants provided written informed 
consent.
The intervention was divided into a 4-month nutritional intervention (phase 
1) and an 8-month maintenance phase (phase 2). In short, in the double-blind 
controlled intervention phase 1, 81 patients were randomized to the PLACEBO 
(n=39) or NUTRITION group (n=42). Both groups underwent a supervised center-
based exercise training program and were advised to consume 3 oral nutritional 
supplements daily. The NUTRITION product provided protein, carbohydrates, fat 
and micronutrients, and was enriched with leucine, omega-3 PUFA and vitamin 
D (Nutricia NV, Zoetermeer, The Netherlands). The PLACEBO product did not 
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comprise the active components, but consisted of a flavored non-caloric cloudified 
aqueous solution. For details see Van de Bool et al. (13).
In the open-label maintenance phase (phase 2), both groups received feedback 
on their daily physical activity behavior twice, based on accelerometry. This was 
done in order to offer both groups a follow-up intervention aimed at maintaining 
long-term efficacy of the exercise training. In addition, participants in NUTRITION 
were advised to take 1 oral nutritional supplement per day and received four 
nutritional counselling sessions. These were provided by trained nurses, and aimed 
to optimize participants' dietary habits and maximize adherence to a healthy diet 
and the supplement regime. The counselling was based on self-determination 
theory (SDT) (20), which assumes that autonomous forms of motivation are 
essential to achieve lasting behavioral change, and it was operationalized through 
motivational interviewing (MI) (21). After the 8-month maintenance phase, 
participants were followed up for three months, without any intervention taking 
place in either group (phase 3). Figure 1 depicts a flowchart of the study; Figure 2 
outlines the study design.
Patients
Patients with COPD (post-bronchodilator FEV1/FVC < 0.7) referred for outpatient 
PR between September 2011 and April 2014 were eligible for participation if they 
had low muscle mass, defined as a fat-free mass index (FFMI) below the sex- and 
age-specific 25th percentile FFMI values (22). Exclusion criteria were age under 18 
years old, allergy or intolerance to components of the study product, investigator's 
uncertainty about patients' willingness or ability to comply with the protocol 
requirements, inability to stop current supplement use, participation in any other 
study involving investigational or marketed products concomitantly or less than 
two weeks prior to entry into the study, pregnancy, or life-threatening diseases.
Outcomes
Quadriceps muscle strength (QMS), assessed by dynamometry (System 4 Pro; 
Biodex Medical Systems Inc., New York, USA) served as the primary outcome of 
this study. QMS, body composition measured by dual energy x-ray absorptiometry 
(DEXA) (Lunar Prodigy system; GE Healthcare, Madison, WI, USA), cycle endurance 
time (CET) on a cycle ergometer (Carefusion, Houten, The Netherlands) 
(determined using the constant work rate cycling endurance test at 75% of the 
peak workload), and fasting plasma levels of vitamin D, eicosapentaenoic acid 












Other diagnosis than COPD (n=471)
FFMI > 25th percentile (n=606)
Inpatient rehabilitation (n=316)
Other exclusion criteria (n=27)
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   Family circumstances (n=1)
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   Withdrawn participation (n=6)
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entering PR), and after phase 1 and 2. Habitual dietary intake of the last month 
was assessed at these time points by trained dieticians using a validated cross-
check dietary history method and calculated using the Dutch Food Composition 
Database. Mental and physical health status, assessed by the Hospital Anxiety and 
Depression Scale (HADS) (23), EuroQoL Five-Dimensions Questionnaire (EQ-5D-
3L) (24), St George's Respiratory Questionnaire (SGRQ) (25) and physical activity 
level (PAL) as assessed by daily steps by a tri-axial GT3X Actigraph accelerometer 
(Health One Technology, Fort Walton Beach, FL, USA) were measured at baseline 
and after phase 1, 2 and 3. Post-bronchodilator forced expiratory volume in 1 
second (FEV1) and forced vital capacity (FVC) were assessed by standardized 
equipment (Masterlab®; Jaeger, Würzburg, Germany), in accordance with the 
latest GOLD guidelines (26). The Dutch value set was used to transform EQ-5D 
scores into utilities (27). Adopting such a wide range of outcome measures is in line 
with the recommendations of the joint ATS/ERS task force on outcome measures 
in COPD to use a multi-outcome approach (28).
Participants' motivational profiles towards exercising and healthy eating were 
assessed using the Behavioral Regulation in Exercise Questionnaire-2 (BREQ-
2) (29) and the Regulation of Eating Behaviors Scale (REBS) (30), respectively, at 
baseline and after phase 1, 2 and 3. These questionnaires are based on SDT and 
they provide six subscale scores (see (20) for details). Answers were given on a 
5-point Likert scale in both questionnaires. Scores on the BREQ range from 1 (lowest 
possible motivation) to 5 (highest possible motivation). Scores on the REBS range 
from 0 (lowest possible motivation) to 10 (highest possible motivation). Internal 
consistency measured by Cronbach's a was adequate for all scales, except for 
identified regulation towards exercising (a = 0.319 after phase 2). Consequently, 
this scale was excluded from subsequent analyses.
Costs
Total costs (not only related to COPD) were calculated from a healthcare and a 
societal perspective. The healthcare perspective included all costs covered by the 
healthcare budget. The societal perspective additionally included travel costs and 
costs of productivity loss due to absence form paid work (absenteeism). Healthcare 
utilization, travel distance and absenteeism were assessed in a resource use 
questionnaire after phase 1, 2 and 3.
The intervention costs included the reported number of supervised exercise 
training sessions and their duration, the number of nutritional supplements used, 
the number of educational counselling sessions and their duration, the number 
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of consultations for physical activity level feedback, the number of nutritional 
counselling sessions and the travel distance to health care providers.
Standard unit costs were determined using Dutch guideline prices (31) and 
inflated to 2015 values using the general consumer price index (32). The costs 
of medication were obtained from the Drug Information System of the Dutch 
National Health Care Institute and included value added tax and pharmacist 
dispensing fees (33). The productivity costs were estimated using the Friction Cost 
Approach, which assumes that productivity loss occurs as long as a sick employee 
is not replaced (the friction period) (34). We used a friction period of 85 days. The 
unit costs are shown in Supplementary Tables 1 through 3.
Statistical analyses
Statistical analyses were performed using Stata, in accordance with the intention-
to-treat principle.
Plasma levels of the supplemented nutrients, body composition, motivational 
profile and physical function were analyzed using a linear repeated measurement 
model with correlated error terms and unstructured covariance matrix. The model 
included treatment, time (i.e., the measurements at 4 and 12 months) and treatment 
by time interactions. Data from patients who discontinued the trial prematurely 
were included in the analyses up to the point of drop-out.
Costs were also analyzed in a linear repeated measures model with correlated 
error terms and unstructured covariance matrix. The dependent variable was total 
costs in a certain phase, and the explanatory variables were time (4, 12 and 15 
months) and the interaction of treatment and time. The results were used to predict 
the mean costs per treatment group for each phase. Total costs were calculated 
as the sum of the predicted costs of the rehabilitation phase, maintenance phase 
and follow-up phase.
To assess differences in health outcomes between the two treatment groups, 
we also used linear repeated measurement models with correlated errors and 
unstructured covariance matrix. Explanatory variables were time (4, 12 [and, if 
applicable, 15] months) and the interaction of treatment and time. We calculated 
the number of quality-adjusted life-years (QALYs) for each patient as the area under 




The costs per gained QALY were calculated as the difference in total costs between 
the two groups divided by the difference in QALYs. Uncertainty around this cost-
effectiveness ratio was estimated by performing 5000 bootstrap replications.
Power calculation 
The power calculation was based on the INTERCOM study assuming a 10% 
between-group difference in peak torque assuming maintenance of skeletal 
muscle strength in NUTRITION during follow-up and a standard deviation of 5 
Nm in peak torque. Allowing for 25% drop-out yielded a subgroup size of n=60. 
Patient inclusion was prematurely discontinued because the test product could not 
be produced within the appropriate quality specifications due to discontinuation 
of the supply of one of the ingredients, but the sample size was justifiable based 
on other RCTs published in the meantime (13).
Results
Patients
Baseline characteristics did not differ between the groups, except for a higher 
peak workload in NUTRITION. The study population consisted of 51% males, 
aged 62.5±0.9 years, and was characterized by low diffusion capacity (DLCO 
49.4±1.7%), moderate airflow limitation (FEV1 55.1±2.2% predicted), normal to 
low BMI (22.7±0.3 kg/m2), impaired exercise capacity (Wmax 63.5±2.4% predicted), 
and low FFMI (15.8±1.6 kg/m2) (see Table 1).
Physical functioning
No between-group difference was observed in improved physical capacity (QMS 
and CET) (see Table 2). When QMS was normalized for appendicular lean mass 
or fat-free mass, the between-group difference was not significant either (data 
not shown). Physical activity level was significantly lower compared to baseline 
in PLACEBO whereas it remained stable in NUTRITION. This led to a significant 
between-group difference on number of steps per day (p=0.025) (see Figure 
3). Activity intensity did not differ significantly over time or between the groups: 
in both groups across all time points, patients spent around 70% in sedentary 
physical activity (PA), 23% in lifestyle PA, 6% in light PA and 1% in moderate-to-
vigorous PA.





   Gender (% male) 42.9% 59.0%
   Age (years) 62.8±1.3 62.2±1.3
   Current smokers (%) 19.0% 31.6%
   Low SES (no or only primary education (%) 5.6% 13.3%
   Employed (%) 33.3% 19.4%
   Number of exacerbations in the last year 1.1±0.2 1.4±0.3
Lung function
   FEV1 (% predicted) 57.0±3.3 53.0±2.8
   FVC (% predicted) 102.8±2.9 100.6±2.7
   FEV1/FVC (%) 44.4±2.0 41.6±1.8
   Functional residual capacity (% predicted) 139.1±4.3 146.7±5.9
   Residual volume (% predicted) 143.4±6.3 153.1±8.5
   DLCO (% predicted) 51.4±2.2 47.1±2.5
Physical function
   Quadriceps muscle strength (Nm) 121.5±6.4 118.0±6.6
   Cycle endurance time (s) 319.0±35.2 231.5±12.0
   Peak workload (Wmax) 84.6±5.2 72.5±3.8
   Peak workload (% predicted) 69.5±3.3** 57.0±3.4
   Physical activity level (steps per day) 4716.7±327.2 4516.6±379.3
Dietary intake
   Energy (kcal) 2426.0±168.0 2442.8±174.2
   Protein (g) 91.1±5.5 89.9±5.5
   Carbohydrates (g) 263.1±19.9 266.8±17.5
   Fat (g) 103.1±9.8 105.4±12.3
   Polyunsaturated fatty acids (g) 20.2±2.0 21.5±2.7
   Cholesterol (mg) 251.5±25.2 239.1±25.2







   Calcium (mg) 1083.5±96.1 977.3±67.5
   Vitamin A (µg) 1241.4±96.5 1192.5±145.8
   Vitamin C (mg) 84.1±6.1 85.9±6.9
   Vitamin D (µg) 5.3±0.4 5.1±0.6
   Vitamin E (mg) 14.6±1.3 13.9±1.2
Supplemented plasma nutrient levels
   Leucine (µmol/l) 147.7±3.6 153.5±3.5
   Vitamin D (nmol/l) 54.0±4.5 45.3±3.1
   Eicosapentaenoic acid (mg/l) 1.1±0.1 1.2±0.1
   Docosahexaenoic acid (mg/l) 2.9±0.2 3.2±0.2
Body composition
   Total weight (kg) 64.3±1.6 65.0±1.7
   Bone mineral content (g) 2331.3±73.0 2414.7±82.3
   Appendicular skeletal muscle mass (kg) 17.4±0.6 18.4±0.6
   Fat mass (kg) 20.0±1.0 19.0±1.3
   Lean mass (kg) 42.0±1.3 43.6±1.2
   Body mass index (kg/m2) 22.9±0.4 22.6±0.5
   Fat-free mass index (kg/m2) 15.7±0.3 15.9±0.2
Patient-reported outcomes
   EuroQoL 5-dimensions questionnaire 0.8±0.0 0.8±0.0
   St George's Respiratory Questionnaire 49.9±2.4 50.1±2.6
   Hospital Anxiety and Depression Scale - total 10.9±1.2 10.2±1.1
All data given as mean ± standard error, unless noted otherwise. DLCO: diffusion capacity of the 
lung for carbon monoxide; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; 
Nm: Newtonmeter; SES: socio-economic status. ** p<0.01.
Table 1 (continued)




Development of physical activity level as change from baseline. # within-group p<0.05 
(compared to baseline); * between-group p<0.05.
The change in physical activity level from baseline to T12 correlated significantly 
with the change in appendicular skeletal muscle mass index (ASMI) (r=0.371, 
p=0.022) but not that in total body weight (r=0.088, n.s.) in the entire study 
population.
Dietary intake and plasma nutrient status
Overall dietary habits represented a typical Western diet and no significant 
within- or between-group changes were identified throughout the trial on any 
macronutrient or micronutrient, except for cholesterol intake (see Supplementary 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Change in total body weight from baseline to T12. * between-group p<0.05.
compared to baseline (p=0.001), leading to a significant between-group difference 
(p=0.003). At baseline, 31.2% of participants had vitamin D insufficiency, whereas 
57.5% had vitamin D deficiency.
Plasma vitamin D, EPA and DHA levels were significantly increased compared 
to baseline in NUTRITION. EPA levels were significantly decreased compared to 
baseline in PLACEBO. Leucine, vitamin D, EPA and DHA levels significantly differed 
between groups (see Table 2).
Body composition
Total body weight, muscle mass and fat mass tended to decrease within PLACEBO 
and tended to increase within NUTRITION from baseline to the end of phase 2. This 
resulted in a significant between-group difference in total body weight change, in 
favor of NUTRITION (D1.54±0.76 kg, p=0.041) (see Table 2 and Figure 4).



























































































































































































































































































































































Total HADS score significantly improved in NUTRITION (p=0.037). In PLACEBO, 
the EQ-5D score decreased significantly (p=0.009) (see Table 2). The SGRQ did 
not differ significantly within or between groups. After phase 3, EQ-5D utility 
was still significantly decreased compared to baseline in PLACEBO (p=0.011), 
whereas the between-group difference was also significant in favor of NUTRITION 
(p=0.034) (see Table 3).
Interestingly, the change in EQ-5D scores from baseline to T12 correlated 
significantly with the change in total body weight (r=0.406, p=0.008) and ASMI 
(r=0.456, p=0.003) in the entire study population.
Motivational profile
Motivation towards both exercising and healthy eating was already high before 
the counselling sessions started. The mean scores for intrinsic and identified 
motivation towards exercising before the counselling started were 4.14 and 4.03 
out of 5, respectively. These figures were 7.69 and 8.42 out of 10 for intrinsic and 
identified motivation towards healthy eating. In NUTRITION, amotivation towards 
exercising decreased (p=0.015) while in PLACEBO identified motivation towards 
healthy eating decreased (p=0.019). Only amotivation towards healthy eating 
differed significantly between groups (p=0.015) (see Table 4).
Intervention costs
Intervention costs are presented in Supplementary Table 1. From a healthcare 
perspective, the mean intervention costs of the total intervention were €2,233 
per patient in NUTRITION and €1,372 in PLACEBO. From a societal perspective, 
these costs were €2,265 and €1,404, respectively. The between-group difference 
is mainly due to the costs of the nutritional supplements. Supervised exercise 
training was the main driver of the intervention costs in both groups.
Total costs and cost-effectiveness
Tables 5 and 6 show the cost-effectiveness analysis after phase 2 and 3. The 
differences in various categories of healthcare utilization over 12 and 15 months 
are presented in Supplementary Tables 2 and 3. After phase 2, the costs in 
NUTRITION were estimated to be €1,529 (certainty 87%) higher than in PLACEBO 
from the healthcare perspective and €2,829 (certainty 98%) higher from the 
societal perspective. After phase 3, costs in NUTRITION were €670 (certainty 64%) 

































































































































































































































































































































































































































































* p<0.05. HCP: healthcare perspective; PAL: physical activity level; QALY: quality-adjusted life year; 
SCP: societal perspective; SGRQ: St George's Respiratory Questionnaire; UI: uncertainty interval.
NUTRITION PLACEBO Difference (95% UI)
Costs (€)
Healthcare perspective 8,094 6,565 1,529 (-1,007 - 4,343)
Societal perspective 9,404 6,575 2,829 (100 - 5,802)
Effects
QALYs 0.66 0.64 0.025 (-0.02 - 0.07)
PAL (steps/day) 4,960 3,940 1,020 (17 - 1,990)
Percentage of patients with +4 
units improvement in SGRQ
0.36 0.43 -0.07 (-0.38 - 0.22)
ICER (€) HCP SCP
Costs / QALY gained 61,160 113,160
Costs / 1000 additional steps 1,499 2,774
Costs / additional patient with 
+4 units improvement in SGRQ
dominated dominated
Table 5
Cost-effectiveness and cost-utility: 12-month time horizon
higher from the healthcare perspective and €2,401 (certainty 92%) higher from 
the societal perspective.
Both from a healthcare and societal perspective, the point-estimates of costs 
pointed towards higher costs in NUTRITION and a higher physical activity level 
in NUTRITION after phase 2, and a higher number of QALYs in NUTRITION after 
phase 3. The probability that the nutritional intervention was cost-effective at a 
willingness-to-pay of €20,000 and €80,000 per QALY was 27% and 59% after 
phase 2 and 55% and 82% after phase 3 (data not shown).
Discussion
This paper investigated the clinical benefits and cost-efficacy of a 12-month 
multimodal, stepwise nutritional intervention strategy in patients with moderate 




Cost-effectiveness and cost-utility: 15-month time horizon
NUTRITION PLACEBO Difference (95% UI)
Costs (€)
Healthcare perspective 9,548 8,878 670 (-2,468 - 4,001)
Societal perspective 11,324 8,923 2,401 (-854 - 5,824)
Effects
QALYs 0.86 0.82 0.04 (-0.01 - 0.10)
PAL (steps/day) 4,576 3,780 814 (-335 - 1,838)
Percentage of patients with +4 
units improvement in SGRQ
0.35 0.23 0.12 (-0.16 - 0.39)
ICER (€) HCP SCP
Costs / QALY gained 16,750 60,025
Costs / 1000 additional steps 823 2,950
Costs / additional patient with 
+4 units improvement in SGRQ
5,583 20,008
COPD and low muscle mass. Physical capacity, as primary outcome, was improved 
in both groups after 12 months, but NUTRITION took 1,030 additional steps per day 
compared to PLACEBO. This difference exceeds the minimal important difference 
to reduce risk of hospital admission (35), and it cannot be explained by greater 
energy substrate availability, as total macronutrient intake was not significantly 
different between the groups at T12 (data not shown). This indicates that nutrient-
specific mechanisms could explain the dissociation between changes in QMS and 
physical activity via various synergistic pathways including immune modulation 
(PUFA, vitamin D) (36, 37), enhancing muscle oxidative metabolism (PUFA) (38) 
and modifying muscle maintenance regulation (PUFA, leucine) (39, 40).
Plasma levels of the supplemented nutrients after 12 months were indeed 
significantly higher in NUTRITION compared to both baseline and PLACEBO, 
indicating that the phased intervention strategy was feasible and overall 
compliance was good.
* p<0.05. HCP: healthcare perspective; PAL: physical activity level; QALY: quality-adjusted life year; 




Trends towards weight gain in NUTRITION and weight loss in PLACEBO after 
12 months led to a significant between-group difference in total body weight. A 
tendency to lose weight in PLACEBO was also found after 12 months in a trial 
focusing on protein-calorie supplementation by Weekes et al. (41). Changes in 
muscle and fat mass parallelled total weight change but were not significant, 
possibly due to lack of power. Remarkably, in contrast to weight change, the subtle 
change in muscle mass correlated significantly with the change in PA.
Previous studies in weight-losing and muscle-wasted patients with advanced COPD 
showed positive short-term (1-4 months) effects of protein-calorie supplementation 
as adjunct to exercise training on physical capacity and muscle mass (42-44), but 
limited evidence is available in less advanced airflow obstruction. The INTERCOM 
trial, which investigated a combined nutritional and exercise intervention in 
the subgroup of patients with low muscle mass and reduced cycle exercise 
capacity, also showed positive effects on muscle mass and physical capacity in 
less advanced COPD patients with low muscle mass (14). However, it could not 
disentangle the relative contributions of the exercise and nutritional interventions 
to physical performance, because the muscle-wasted control group only received 
usual care. In the 20-month maintenance phase of the INTERCOM trial, physical 
capacity remained improved in the subgroup of treated muscle-wasted patients, 
but 6-minute walking distance declined below baseline in those receiving usual 
care (14). Whereas the nutritional intervention strategy had no short- or long-term 
added value on physical capacity in the current trial (13), there were sustained 
positive effects on body weight, plasma nutrient levels and physical activity and 
a trend towards improved mental health, which could explain the difference in 
generic health status after follow-up.
Both EQ-5D and physical activity levels remained stable in NUTRITION and 
declined in PLACEBO after 12 and 15 months. These parallel changes could 
mean that generic health status is influenced by daily physical activity level via 
modulation of physiological and / or mental health.
A qualitative study in a random sample of 22 NUTRAIN participants after phase 2 
identified perceived competence and autonomous motivation as determinants of a 
physically active lifestyle (45). The limited between-group motivational differences 
could be partly explained by high levels of both intrinsic and extrinsic motivation 
and low levels of amotivation already apparent before counselling. Admission 
to PR already requires being motivated and participating in an extensive study 
such as this one even more so. Even so, slight changes in motivational profile may 
indicate some effect of the nutritional counselling.
Nutritional intervention in COPD and low muscle mass: the NUTRAIN trial
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The incremental cost-effectiveness ratio (ICER) of €61,160 after phase 2 decreased 
to €16,750 after phase 3, because of a higher gain in QALYs and lower difference 
in costs after phase 3. Whether an intervention is cost-effective or not depends 
on the threshold value of the willingness-to-pay for a QALY. In The Netherlands 
this threshold depends on disease burden (defined as proportional shortfall) (46). 
A higher threshold applies for conditions with a higher disease burden. There 
are three categories, defining a low burden (proportional shortfall of 0.1-0.4 
QALYs), medium (0.41-0.7) and high burden of disease (0.71-1), corresponding 
of threshold values of €20,000, €50,000 and €80,000 per QALY, respectively (47). 
Hence, an ICER below €20,000 (after phase 3) is generally considered to be cost-
effective. With an ICER of around €60,000 after phase 2, the current nutritional 
intervention would be cost-effective for COPD patients with a disease burden of 
at least 0.7 QALYs. However, this estimation is associated with high uncertainty 
illustrated by a small proportion of bootstrap replications below a threshold value 
of €80,000 after phase 2.
A weakness of the current study includes the unblinding after PR, which was done 
because it was considered unethical to continue placebo supplementation during 
the maintenance phase. Secondly, as already mentioned, the current study included 
quite a small number of patients, in line with many other comparable studies. 
Generalizability of the study is limited by the fact that only patients referred for PR 
were included. Thirdly, not achieving the sample size specified beforehand could 
limit our ability to detect significant results. Finally, the counselling sessions were 
given by nurses who lacked detailed knowledge on the domains to be improved. 
More detailed and tailored advice could improve adherence to a healthy lifestyle 
and increase health gains.
Conclusion
A stepwise multimodal nutritional intervention strategy, consisting of targeted 
nutritional supplementation and nutritional counselling, in muscle-wasted 
patients with moderate COPD does not enhance long-term outcome of exercise 
training on physical capacity but ameliorates plasma levels of the supplemented 
nutrients, body weight, physical activity and generic health status. This intervention 
increases total health care costs to a degree that might be considered acceptable 
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Introduction: Cognitive impairment (CI) is an important but under-recognized 
extra-pulmonary feature of chronic obstructive pulmonary disease (COPD). It is 
related to the burden of disability, worse health outcomes, and impaired self-
management.
Areas covered: CI includes deterioration of a wide range of cognitive functions, 
such as memory and various executive functions. Risk of hospitalization might 
be higher in patients with COPD compared to those without, with CI negatively 
impacting the wellbeing of patients with COPD. Disease-specific factors such as 
hypoxemia and inflammation, lifestyle factors such as dietary insufficiencies and 
lack of physical activity, and comorbidities such as obstructive sleep apnea and 
depression are likely to synergistically contribute to the development of CI in 
COPD. Tailored interventions can possibly improve CI in COPD, but this needs 
further investigation.
Expert commentary: Further research is warranted involving the optimization of 
neuropsychological testing for screening and outcome assessment, longitudinal 
studies to investigate the development of CI in COPD over time, and randomized 
clinical trials to test the feasibility and efficacy of promising interventions.
Cognitive impairment in COPD: 




Chronic obstructive pulmonary disease (COPD) is a chronic lung disease 
characterized by persistent respiratory symptoms and airflow limitation due to 
airway and / or alveolar abnormalities (1). It is well established that common extra-
pulmonary comorbidities such as heart failure, osteoporosis and muscle wasting 
contribute significantly to the disease burden (2). Moreover, recent research 
shows that cognitive impairment (CI) is also a common and important, yet under-
investigated comorbidity (3). This review will discuss various aspects related to CI in 
COPD: its prevalence and characteristics, related health outcomes, determinants, 
and possible interventions to maintain or improve cognitive functioning in patients 
with COPD.
Cognitive functioning
Cognition can be defined as any brain function that enables an individual to 
perceive, register, store, retrieve and use information in order to adapt behavior 
to new situations and function in our environment (4). Cognition consists of many 
separate domains, including memory, working memory and attention (5).
Cognition is organized hierarchically and different cognitive functions can be 
classified as 'lower' or 'higher' (6) (see Figure 1). The lower functions form the 
basis for the higher functions, including the executive functions such as inhibition 
(choosing an option that is more rewarding in the longer term instead of the more 
immediately satisfying option when presented with a choice, for example refusing 
the attempt to smoke a cigarette) and cognitive flexibility (being able to swiftly shift 
mental resources, for example changing the type of physical activity undertaken 
in case of weather changes) (7). Executive functioning in turn underlies even more 
complex processes such as problem solving and decision making, for example 
when and how to undertake action in case of increased symptom severity (e.g., 
disease exacerbation or unintended weight loss).
Specific brain areas do not exclusively perform a single task, but many brain areas 
are specialized for certain types of tasks (see Figures 2 and 3). The language and 
memory systems are largely located in the temporal lobe, whereas the higher-order 
functions such as inhibition, cognitive flexibility, reasoning and decision-making 
are processed in the frontal lobe. Subcortical structures are located within the 
brain, including the hippocampus, which plays a central role in memory encoding; 





A hierarchical view of cognitive processes. Adapted from Cleutjens et al. (4).
in fear and pain processing; and the basal ganglia, including the caudate nucleus, 
which is involved in movement but also in learning and remembering (8).
Brain damage, for instance caused by brain atrophy or degeneration, can contribute 
to the development of CI. This is an inevitable part of aging, but acute and chronic 
disease can accelerate it. In the initial stages of CI development, impairments 
are noticeable, but not severe enough to impair activities of daily living; a stage 
called mild cognitive impairment (MCI) (5). MCI often, but not always, involves 
impairments in memory rather than in other domains (9), and it may progress into 
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View of the left cerebral hemisphere, indicating the areas mentioned in the text. Adapted 
from Patrick J. Lynch, medical illustrator, and Carl C. Jaffe, MD, cardiologist.
Cognitive impairment in COPD
Patients with COPD display impairment in cognitive domains as diverse as 
attention, executive functioning (3, 11-13), (visual) memory and reproduction (14, 
15), problem solving, concentration, logical and abstract reasoning, planning, 
coordination and organization (3). Thus, the pattern of impairments is diffuse, and 
not every patient is affected or suffers from CI to the same degree in different 
cognitive domains (16). This diffuse pattern resembles aging-related cognitive 
deterioration and is consistent with the view of CI in COPD as a manifestation of 
accelerated ageing (3). On the other hand, patients with Alzheimer's disease or 




































Sagittal view of the brain, indicating the areas mentioned in the text. Adapted from Patrick J. 
Lynch, medical illustrator, and C. Carl Jaffe, MD, cardiologist.
Prevalence
Cross-sectional studies
A recent meta-analysis pooled 14 studies investigating the prevalence of CI in 
COPD patients (17). The average prevalence of any CI (5 studies, N=2,995) was 
32%. MCI was present in 25% of patients (11 studies, N=4,663). Higher prevalence 
of CI was associated with respiratory disease severity, dependence in activities of 
daily living and poor quality of life (17).
Studies published after this meta-analysis (25 February 2016) show an even 
higher prevalence of CI (see Table 1). Two studies by Cleutjens et al. reported CI, 
determined by extensive neuropsychological assessment, in 56.7% and 41.5% of 
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study only 13.3% of non-COPD age-matched controls suffered from CI. Pierobon 
et al. showed that the Montreal Cognitive Assessment (MoCA) score of 9.5% of 
patients admitted to PR was below the 5th percentile of a normal reference group, 
and only 38.1% scored higher than the median (20). This may be related to the 
fact that patients referred for PR generally have moderate to advanced disease. 
Roncero et al. showed CI in 39.4% of stable COPD patients. This study was large 
(N=940), but it only assessed cognition using the Mini-Mental State Examination 
(MMSE) (21), which is useful as a screening tool but not as a diagnostic tool (22). 
Samareh Fekri et al. likewise administered the MMSE to 87 COPD patients and 
60 age- and gender-matched individuals. MCI was present in 44.8% of patients 
with COPD and moderate CI in 6.9%, compared to 33.3% and 3.3%, respectively, 
in controls (23). It is not reported whether these percentages differ significantly, 
but the mean MMSE score in the COPD group was significantly lower than in the 
control group (22.51±2.4 versus 23.63±2.8, respectively).
Lopez-Torres et al. investigated cognition during hospitalization for an exacerbation, 
at discharge and after return to a stable state (25). Cognitive functioning measured 
by MoCA scores increased significantly from hospitalization to discharge and 
decreased again from discharge to stable state, but to a higher level than at 
hospitalization.
In summary, a wide range of prevalences is reported for CI in COPD. The 
heterogeneity of applied cognitive tests and cut-off points to define CI as well 
as diverse study populations (community-dwelling, pulmonary rehabilitation, 
hospitalized patients et cetera) likely contributes to this wide range.
Longitudinal studies
Future research using longitudinal designs may elucidate the development of CI 
in COPD over several years and the influence of disease progression and other 
factors in different disease stages. The longitudinal studies already conducted 
have shown some interesting results. A self-reported diagnosis of COPD in 
midlife increased the risk of developing CI later in life (odds ratio [OR] 1.85, 95% 
confidence interval [CI95] 1.05-3.28), but COPD diagnosed later in life was non-
significantly inversely related to CI (OR 0.30, CI95 0.08-1.24) (26). This surprising 
result might be explained by survival bias rather than the effects of COPD itself 
(26). In a recent study 32.6% of patients taking part in the National Emphysema 
Treatment Trial (NETT) were impaired on part B of the Trail Making Test (TMT) 
at baseline (27). This test measures task switching, which is part of executive 
functioning. No prevalence estimates were given for subsequent time points, 
but TMT-B performance was virtually unchanged over the 3-year follow-up. Most 
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remarkably, the sample could be distinguished into four clusters based on their 
trajectories of cognitive development over three years. One cluster (35.5%) had 
low baseline TMT-B scores and improving scores over time, the second (39.7%) 
had low baseline and worsening scores, the third (18.2%) had high baseline and 
worsening scores, and the fourth (6.5%) had high baseline and improving scores.
Cerebral abnormalities
CI is associated with global and/or specific cerebral abnormalities, and many 
studies have found structural or functional abnormalities in patients with COPD, 
along with elevated serum levels of S100B, a putative marker for brain damage 
(28).
Cortical degeneration (29-32), increased occurrence of small vessel disease (33) 
or abnormal functional activation on a global level is uncommon in COPD, with 
a few exceptions. Two studies found overall increased white matter (WM) lesion 
volumes and decreased WM integrity (30, 31), and cortical thickness and volume 
were globally reduced in patients who were hospitalized for 30-45 days following 
an exacerbation (34). 
Regional changes are more common. Gray matter (GM) was found to be decreased 
in many brain regions in both hemispheres, among others in the dorsolateral 
prefrontal cortex (34), which is involved in higher functions and working memory 
(35); different areas involved in visuospatial processing (36); the frontal cortex; and 
limbic and paralimbic structures (15, 29), which are mainly involved in emotion 
processing and memory (37). Disease duration was inversely related to GM 
volume in various, mainly subcortical, regions (12, 29), but not in others, including 
the hippocampus and amygdala (29). 
Reduced WM integrity in the superior and middle frontal gyri and right occipital 
subcortical WM was shown in patients with moderate COPD (32). WM integrity was 
more reduced in the bilateral frontal subcortical areas, right temporal lobe and 
pons in severe compared to moderate COPD. Patients with an acute exacerbation 
who had been hospitalized for several weeks also showed reduced WM integrity 
compared to healthy controls in various (para)limbic regions (12). However, 
Cleutjens et al. (33) showed that cognitively weak and cognitively strong patients 
with COPD had equal amounts of WM hyperintensities (WMH).
Two studies investigated the relation between lung function and brain volume 
in healthy elderly. One study reported a significant correlation between forced 
expiratory volume in 1 second (FEV1) and overall brain atrophy and ventricle-to-




ratio was correlated with WMH in the sample as a whole. Participants with and 
without chronic respiratory disease did not differ on any clinical or brain imaging 
parameter. Moreover, no control variables were included. The second study only 
showed a significant positive relationship between FEV1 and cerebellar WM 
volume, but no generalized cortical degeneration (39).
The hippocampus is interesting as it is vital in memory formation and learning, 
and only one of the two regions to display neurogenesis in the adult human brain 
(40). As such, decreased hippocampal volume could also indicate abnormalities 
in brain plasticity in patients with COPD, but findings are mixed. In one study, 
hippocampal volume was decreased in COPD compared to healthy controls 
and its size was related to partial oxygen pressure and oxygen saturation (41). 
Hippocampal volume did not differ between patients with mild-to-moderate 
COPD and those with severe COPD (41). In another study, however, hippocampal 
volume was not significantly different between patients with COPD and controls 
(42), and it has also been shown to not differ between cognitively strong and 
cognitively weak patients with COPD (33). 
Functional abnormalities were reported in the left precentral and postcentral gyri 
and the left caudate nucleus when comparing patients with COPD with controls 
matched on age, sex and education (14). Evidence on resting state network and 
default mode network activity is mixed. These networks are distinct from others 
because their activity increases when the brain is not engaged with other tasks (43). 
Their increased activation could hinder cognition by interfering with task-related 
activity. One study found increased resting state network activity in patients with 
COPD compared to healthy controls, but this result was not significant anymore 
after controlling for oxygen saturation (14). Another study also found increased 
default network activation in patients with moderate COPD, but decreased 
activation in those with severe COPD (44). This result might reflect a compensatory 
response to damage inflicted by factors associated with COPD, and this response 
might be strongest in patients with moderate COPD (44).
The structural and functional abnormalities discussed above reflect a gradual 
influence of COPD on the brain. However, COPD can also heighten the risk of 
more acute events, such as stroke. This is likely due to high levels of systemic 
inflammation and oxidative stress, possibly as a result of smoking, leading to 
endothelial dysfunction, decreased vascular reactivity, thickening of the carotid 
artery wall and atherosclerotic plaque rupture (45). An elevated risk of stroke in 
patients with COPD was found in several studies (hazard ratios [HRs] 1.09 [CI95 
0.91-1.31] and 1.24 [CI95 1.19-1.28]) (46, 47) and meta-analyses (HRs 1.30 [CI95 
1.09-2.09]) (48, 49). The significance in the latter study was probably due to the 
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large sample size (N=132,017 versus 1,566 in the former). HRs are roughly equal 
for the ischemic, hemorrhagic, intracerebral and subarachnoid hemorrhagic 
subtypes. However, in the weeks after an acute exacerbation, the HR increased to 
6.66 (CI95 2.42-18.20) (46).
In conclusion, patients with COPD show an increased prevalence of many different 
types of cerebral abnormalities, compared to healthy controls. Patients with COPD 
have reduced gray and WM volume in various brain areas and WM integrity is 
compromised. It is still equivocal whether hippocampal volume is decreased 
in patients with COPD. There is evidence for abnormal functional activation, 
particularly in the resting state and default mode networks. The abnormalities are 
spread throughout the brain rather than concentrated in one or some areas. This 
could possibly explain the diffuse pattern of CI found in COPD.
Figure 4
The possible relationships between cognitive impairment and clinical outcomes. Dotted 



























CI and health outcomes in COPD
CI has a wide range of adverse effects on self-management skills and other health 
outcomes in patients with COPD (see Figure 4).
Self-management skills
Self-management skills are of major importance for patients with COPD. 
Symptoms may vary from day to day and increased symptoms may be caused by 
exacerbations. Patients need to recognize and act upon these exacerbations in 
an adequate manner (50). Moreover, patients need to adhere to their medication 
and need to adopt a healthy lifestyle, including a healthy diet and physical activity. 
Smokers need to quit smoking. This often requires a behavior change, which 
poses a demand on cognitive functioning (50). It is therefore feasible that CI limits 
the ability to cope with the daily challenges of living with COPD.
A recent systematic review revealed that there was just one study in which the 
impact of CI on self-management skills in patients with COPD was investigated 
(51). This particular study, including 100 participants with COPD, showed no 
relationship between cognitive functioning assessed with the MoCA and overall 
self-management abilities, as measured by the Self Management Ability Score 
30 (SMAS30). SMAS30 assesses the following: taking initiatives, investment 
behavior, variety, multifunctionality, self-efficacy, and positive frame of mind. 
Moreover, living alone affected the interaction between cognitive functioning 
and self-management abilities (52). In fact, only among patients who lived alone, 
better cognitive functioning was related to lower self-management abilities 
(52). Emotional intelligence (defined as the capacity to understand and manage 
personal thoughts and feelings, as well as to positively influence interpersonal 
communication and social well-being), however, seems to be related to self-
management abilities in COPD (53).
Meek et al. (54) showed a relationship between MMSE scores and the ability to 
accurately recall severity of fatigue and dyspnea in the previous two weeks. It is 
reasonable to assume that this might impact on the ability to recognize and act 
upon symptoms of an exacerbation, but the exact relationship remains unknown.
The relationship between CI and inhaler competency is well-known (51). An 
MMSE score of 23-24 points or less is predictive of poor inhaler technique, as 
are impaired executive functioning and impaired praxis. While some inhalers 
may be more difficult to use than others, recognizing CI is of major importance 
when prescribing inhaler devices as well as providing instructions to use them 
(51). Some studies suggest Turbohalers might be easier to use for patients 
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with CI than metered dose inhalers (51, 55). To our knowledge, however, there 
are no recommendations specifically on inhaler use for COPD patients with CI. 
Nevertheless, inhaler competency is a major consideration when prescribing 
inhalers and should be checked regularly. 
Brega et al. (56) showed that older persons with impaired executive functioning 
were less likely to quit smoking than those with normal executive functioning. 
However, recent data did not confirm the relationship between executive 
cognitive dysfunction and smoking cessation (57). Moreover, another study even 
showed that persons over 75 years of age who quit smoking had lower cognitive 
functioning than persons who continued smoking (58). Differences in findings 
about the relationship between smoking and cognition might be explained by 
the fact that patients in the last study were older and different methods were 
used to assess cognitive functioning. Cleutjens et al. did not find a statistically 
significant difference in smoking status between patients with COPD entering PR 
with or without CI (19). Therefore, whether and to what extent CI limits the ability 
of patients with COPD to quit smoking remains unclear.
Health outcomes
CI seems related to functional exercise capacity as measured by 6-minute walking 
distance (59, 60). Nevertheless, this was not confirmed among patients entering 
PR (19) or during an exacerbation (59).
Cleutjens et al. showed that the response after completion of a PR program was 
similar in patients with CI compared to those without (61). However, patients 
with CI were more likely to drop out compared to those without CI (23.3% versus 
10.3%, respectively). Therefore, timely recognition of CI in patients entering PR 
seems paramount.
Several studies showed an inverse relationship between CI and HRQoL as assessed 
with the COPD Assessment Test (21, 60), the EuroQoL-5 dimensions questionnaire 
(21), or St George's Respiratory Questionnaire (22). Then again, other studies did 
not confirm this relationship (19, 62).
The systematic review of Baird et al. included four studies exploring the 
relationship between CI and disability and showed that CI is related to impairment 
in basic activities of daily living, instrumental activities of daily living, work and 
social activities (51). Martinez et al. found that COPD and CI have independent but 




The co-existence of CI and COPD is associated with a more than fourfold increased 
risk of hospitalization for respiratory-related illnesses and a 34% higher risk of all-
cause hospitalization compared to healthy controls, after controlling for various 
sociodemographic variables, smoking status and comorbidities (64). Moreover, 
CI seems to be related to an increased length of hospitalization (22). Data from 
the NETT trial did not show an association between impairment in executive 
functioning and frequency of hospitalization (65).
A study including stable patients with COPD even showed that drawing 
impairment predicted increased mortality risk (66). Nevertheless, Yohannes et al. 
found that MMSE scores did not predict 1-year all-cause mortality (67). Moreover, 
only a modest association was found between executive function and survival in 
the NETT trial (65).
In conclusion, CI may negatively impact self-management and health outcomes 
in COPD, but the current literature is conflicting and many questions remain. 
The conflicting literature may be explained by different methods used to assess 
cognitive functioning and criteria used to define CI. Moreover, there were 
major differences between the studied populations. The complex cause-effect 
relationships also make this field very challenging. COPD may influence self-
management skills, but poor self-management in turn also worsens COPD disease 
progression, thereby creating a vicious cycle.
Determinants of COPD-induced cognitive impairment
Factors such as hypoxemia, hypercapnia, inflammation and lifestyle factors may 
all contribute to structural and functional cerebral abnormalities and CI. Any 
individual factor probably does not explain a significant amount of CI, but their 
synergistic effects may be large (11, 68).
Hypoxemia and hypercapnia
Hypoxemia and hypercapnia are hallmarks of severe COPD (69) which can also 
negatively affect cognition (70, 71). Hypoxemia alters the microenvironment 
around neurons (72) and induces impairments in spontaneous and task-stimulated 
neuronal activity (73, 74). Hypoxemia might underlie decreases in GM density (12, 
15), and mild hypercapnia decreases functional connectivity in almost all brain 
lobes (75). The exact mechanisms through which this happens are still unclear (75). 
Diminished vasodilatation in response to hypoxemia or hypercapnia in patients 
with COPD might be one (76).
Cognitive impairment in COPD: 




Multiple lines of evidence indicate that systemic inflammation might underlie CI in 
COPD. Low-grade systemic inflammation is linked to decreased cognition in other 
conditions including obesity (77, 78) and metabolic syndrome (79, 80). In the 
general population c-reactive protein (CRP) and interleukin-6 levels were related 
to global cognition and executive functioning, whereas a1-antichymotrypsin 
was not (79). MoCA scores have been found to be negatively correlated with 
CRP, fibrinogen and erythrocyte sedimentation rate levels (82). The relationship 
between inflammation and cognition in stable COPD has not been thoroughly 
investigated yet. Next to low-grade systemic inflammation, patients with COPD 
may experience periods of an enhanced systemic inflammatory response related 
to disease exacerbations that will be discussed later.
Respiratory medication
Long-acting b-adrenoreceptor agonists (LABA), long-acting muscarinic antagonists 
(LAMA) and inhaled corticosteroids are frequently prescribed to patients with 
COPD (1).
Some literature has associated anticholinergic use with increased risk of MCI (83) 
and dementia (83-85), and faster cognitive decline (86). However, participants in 
these studies used systemic rather than inhaled medication. Inhaled medication 
is much more targeted and will therefore have much less systemic effects. For 
example, tiotropium cannot cross the blood-brain barrier (87) which might 
suggest no or limited effect on cognitive functioning. However, no studies have 
investigated the effects of tiotropium on cognition yet.
The effects of corticosteroids or glucocorticoids (GC) on cognition have not been 
investigated in patients with COPD yet either. In general, mildly elevated GC levels 
improve cognition (88), but long-term administration can cause 'steroid dementia', 
characterized by impairments in episodic, declarative and working memory and 
executive function, and associated hippocampal and prefrontal dysfunction (89). 
Steroid dementia can appear within weeks of commencing GC treatment and is 
largely reversible upon its termination, although impairments can remain for years 
after termination (89, 90).
It is doubtful whether steroid dementia is a real risk in COPD. The recommended 
dose and duration for patients with an acute exacerbation (30-40 mg of prednisone 
daily for 7 to 14 days, where 5 days may be equally effective) (91) are much lower 
and shorter than those reported to cause steroid dementia (i.e., 60 mg/day for 7 




In conclusion, to date, evidence that respiratory medication can contribute to 
impaired cognition in patients with COPD is lacking.
Exacerbations
During acute exacerbations the above-mentioned determinants intensify and 
converge. Interestingly, exacerbations have an additional detrimental effect on 
cognition (22, 82, 92, 93). During acute exacerbations, levels of inflammation and 
cognitive functioning are inversely related (94), and as recovery from exacerbation-
related CI seems very slow to non-existent, it can be speculated that regular COPD 
exacerbations can trigger a stepwise decrease in cognition. One study found 
no improvement in the 3 months after an exacerbation (22). However, because 
these patients were not cognitively tested prior to the exacerbation, it cannot be 
determined whether the exacerbation actually affected cognition in this study.
Comorbidities
COPD often presents with comorbid conditions such as obstructive sleep apnea 
(OSA), depression and chronic heart failure (CHF), and a recent systematic review 
reported an increased risk prevalence of the metabolic syndrome in COPD 
compared to matched controls (95).
OSA contributes to decreased arterial oxygen saturation (96), causes sleep 
fragmentation and cortical and sympathetic arousal (96, 97), and affects 
attention, memory, psychomotor speed, visuospatial abilities, constructional 
abilities, executive functions and language abilities (96, 98). Hypoxemia, a shared 
component between OSA and advanced COPD, might underlie the cognitive 
deficits apparent in both diseases, namely attention, memory, executive function, 
psychomotor function and language abilities (98).
Depression is associated with decreased cognitive functioning (99) in COPD, but it 
probably only predicts 1-2% of the variation in cognition (3). A study investigating 
cognitive bias in patients with COPD and healthy controls with and without 
depression revealed that depressed patients with COPD showed a comparable 
pattern of bias compared to depressed healthy controls, whereas never-depressed 
patients showed much less bias (100). In conclusion, the influence of concurrent 
COPD and depression on cognition is still equivocal.
Many patients with COPD also suffer from CHF, and vice versa (17). The prevalence 
of CI in CHF is largely unknown, as prevalence estimates between 13.5% and 
80% have been reported (17). CHF and COPD might have additive effects on 
cognition. Moreover, COPD and CHF are both associated with a high prevalence 
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of cerebrovascular diseases, which could lead to chronic cerebral hypoxia, 
impaired brain perfusion and ultimately brain damage and cognitive impairment 
(17). Furthermore, etiological similarities, such as cigarette smoking, may lead to a 
common set of symptoms, including CI (17).
Metabolic syndrome (MetS) is a cluster of metabolic risk factors, such as central 
obesity, dyslipidemia, hyperglycemia and dyslipidemia (95), with a prevalence of 
34% in patients with COPD (95). MetS is strongly related to the risk of developing 
type 2 diabetes and cardiovascular disease (95) and has also been shown to have 
a deleterious influence on cognition (101, 102). However, some research also 
suggests that certain components of MetS have a larger effect than others (103, 
104). It is yet unclear what the relative contribution of each of the components of 
MetS on cognition is.
Smoking
Smoking is one of the largest risk factors for developing lung cancer or COPD, 
and it affects cognition in multiple ways. Firstly, it increases carbon monoxide and 
carbon dioxide levels in the blood, causing hypercapnia (105) and hypoxemia 
(106), respectively. Secondly, cigarette smoke contains many neurotoxic 
components, such as cadmium, nitric oxide and lead (107). Thirdly, the many 
free radicals in cigarette smoke are neurotoxic (108). And finally, chronic nicotine 
administration increases tau phosphorylation, a key component of Alzheimer's 
disease pathophysiology (107) and induced free radical production and depleted 
antioxidant levels in a rat model (109). Ultimately, all of these components cause 
decreased GM and WM volume and connectivity, and impair cognition (110-112).
Only one study investigated the influence of smoking on CI specifically in patients 
with COPD (113). Cognitive performance of patients with COPD was comparable 
to that of smokers, but both were significantly worse compared to normal reference 
values. The number of pack years and the duration of abstinence of the past 
smokers, consisting almost two-thirds of the sample, was not reported. Therefore, 
it cannot be determined with certainty to which degree smoking affects cognition 
beyond the effects of COPD. In general, smoking per se contributes to cognitive 
dysfunction, but there is also evidence of a relationship between impaired lung 
function and cognition independent of smoking (3, 114).
Dietary insufficiencies
Diet and nutritional habits significantly impact on brain fitness, mental and cognitive 
health throughout life (115, 116). The relative abundance of specific dietary 




health and cognitive ability via direct and indirect mechanisms that modulate 
neuronal function and synaptic plasticity (117). Chronic stress has been shown 
to negatively impact on brain plasticity and cognitive performance, for instance 
through the harmful effects of cortisol (118-120) and poor dietary habits are 
hypothesized to correlate with heightened stress reactivity and susceptibility (121) 
and greater cognitive decline in elderly (122). A healthy diet, rich in polyphenols, 
B vitamins, polyunsaturated fatty acids and dietary fibers exert favorable effects 
on cognitive performance, stress reactivity and neuroinflammation (117, 123). 
Unintended weight loss and muscle wasting is common in advanced COPD, 
but specific nutritional deficiencies that could affect cognition have received 
limited attention to date. However, next to disease severity, Collins et al. 
recently highlighted in a UK COPD population the importance of deprivation on 
malnutrition risk (124). An Australian study reported, next to low muscle mass, a 
high prevalence of deficiencies in vitamin D, vitamin B12 and iron in patients with 
COPD hospitalized with an acute exacerbation (125). A Dutch study investigating 
patients eligible for PR reported that vitamin D and calcium intake were below the 
recommended levels in more than 75% of patients, whereas vitamin A, C and E 
intakes were below the recommended levels in over one-third of patients (126). 
No studies have yet investigated the relationship between nutritional status or 
dietary pattern and cognitive performance in COPD.
Inactive lifestyle
Higher levels of physical activity are associated with a reduced risk of cognitive 
decline and dementia (127). However, disease-related factors such as dyspnea 
and muscular metabolic abnormalities make it hard for many patients with COPD 
to be physically active. One systematic review found a mean daily step count of 
2,237 (128), which is far less than the threshold for a low active (5,000 steps) or 
active lifestyle (10,000 steps) indicated by the same authors (128). Low physical 
activity levels and a sedentary lifestyle negatively impact on cognition in the 
general population (129, 130), and as such may contribute to CI in COPD as well.
Overall, disease-specific as well as lifestyle factors may contribute to the 
development of CI in COPD, but the relative potential synergistic contributions of 
the individual factors are yet unclear.
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Cognitive training can improve cognitive functioning in healthy elderly adults 
(131, 132), and can also improve some cognitive domains in those with MCI (131). 
Research into cognitive training specifically for patients with COPD is scarce. One 
trial attempted to ameliorate cognition in hypoxemic patients with COPD through 
an intervention aimed at improving attention, learning and logical-deductive 
thinking (133). During the first 2 weeks, the intervention group received group 
cognitive training, in the four weeks thereafter they received individual training, 
followed by home assignments two times per week. Booster sessions took place 
after 3 and 5 months. The control group received usual care and no cognitive 
training. Some cognitive domains improved in both the intervention and placebo 
group, but the intervention had no additional effect on cognition.
Exercise training
Exercise can improve cognition through multiple pathways. It causes an increase in 
cerebral blood flow (38) and levels of cerebral growth factors such as brain-derived 
neurotrophic factor (134) and insulin growth factor-1 (135). These growth factors 
are involved in many functions which are important for cognition. They influence 
the rate of differentiation and apoptosis of cerebral cells (136), and regulate long-
term potentiation (137) and hippocampal neurogenesis (136). Multiple previous 
studies have shown the benefit of exercise on cognition in COPD patients (138, 
139), and in the study by Park et al. the 6-minute walking distance was the only 
potentially modifiable variable that was related to worsening cognitive functioning 
over time (27). The question remains, however, whether these improvements 
consolidate into the longer term if exercise is discontinued (11).
Smoking cessation
Given the deleterious influences of smoking on cognition, it is unsurprising that 
smoking cessation is beneficial. However, its effects on cognitive functioning have 
only been assessed in the general population. It appears that the number of pack 
years negatively affects cognitive functioning, but also that cognitive functioning 
improves with longer duration of abstinence (140). This implies that abstinence 
pays off at any age, with the largest benefits coming to those who stop the earliest. 
Future research should further investigate the effects of smoking cessation on 





Dietary intervention may imply adopting a different dietary pattern or 
supplementing the habitual diet with specific nutrients. The Mediterranean diet, 
the Dietary Approach to Stop Hypertension (DASH) diet and the Mediterranean-
DASH Intervention for Neurodegenerative Delay (MIND) diet have been proposed 
as beneficial to cognition (141-143). Drastic dietary changes, however, are not 
likely to be feasible for patients with advanced COPD.
These interventions imply that CI in COPD is not something that patients have to 
passively undergo but can be readily applied in daily life. However, more research 
is needed to assess the feasibility and efficacy of the individual interventions or 
multimodalities thereof.
Conclusion
CI in patients with COPD is a problem with a high prevalence and large 
consequences, yet it is still under-recognized and under-investigated. More 
research aimed at unraveling the etiology and appropriate interventions to 
diminish cognitive decline or treat CI in patients with COPD is needed to benefit 
the patients as well as their loved ones.
Caregivers should pay more attention to potential CI in their patients, as CI may 
have large consequences on self-management and health outcomes. In a clinical 
context, administering a brief screening tool may help in identifying patients who 
need referral to a specialist for further investigation. These patients also need 
more time and attention, for instance while making sure they understand how to 
properly use their medication.
Expert commentary
Technical developments in the field of cognitive neuroscience enable more detailed 
insight in the pathophysiology of CI in COPD. Increasing magnetic resonance 
imaging resolution allows a more detailed picture of the brain, techniques such 
as diffusion tensor imaging allow focusing specifically on white matter instead of 
the brain as a whole, and shorter and more effective scanning protocols can make 
brain imaging more accessible and affordable.
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Investigating novel research directions might also be worthwhile. For instance, 
the synthesis and proper functioning of many neurotransmitters, including the 
catecholamines, glutamate, aspartate and perhaps most importantly acetylcholine 
(as it is widely available in the brain but also the most important neurotransmitter in 
the airways) depend on oxygen availability (144). Hypoxia-based neurotransmitter 
abnormalities might therefore constitute a third type of cerebral abnormality 
contributing to CI, next to structural and functional abnormalities. However, this 
has received scarce research attention to date in the general population, and 
especially in COPD.
Longitudinal studies are essential for understanding the causes and consequences 
of CI in COPD. They can elucidate the development of cognitive decline in COPD in 
relation to the development of other potentially relevant variables such as impaired 
lung function, hypoxia or inflammation. In this way, the relative contributions of 
disease- and aging-related factors can also be further disentangled.
Interesting treatment options for CI in COPD include the potential role of specific 
nutrients in ameliorating cognition. The Mediterranean diet, which is characterized 
by a high intake of plant-based foods, moderate-to-high fish and seafood 
consumption and scarce use of dairy products and meat (141), has earlier been 
shown to improve cognition in a randomized controlled trial (141). Furthermore, 
polyunsaturated fatty acids and polyphenols can ameliorate cognition and have a 
positive effect on various neurobiological processes (145). Also, testing potential 
synergistic effects of combinations of interventions could be worthwhile, such as 
exercise training and cognitive training.
An important prerequisite for all the above research questions is the choice of the 
right cognitive test instruments. Often applied screening tools such as the MMSE 
or MoCA can be useful in a clinical setting to identify patients in need of further 
neuropsychological assessment and therapy, but cannot give a detailed overview 
of the exact nature of a person's deficits. Larger, well-defined and evidence-based 
test batteries are essential in order to get a comprehensive overview of a person's 
neuropsychological functioning (146).
Five-year view
In conclusion, it is important to further investigate the pathophysiology, causes 
and consequences of CI in COPD in the next five years, and to develop tailored 
intervention strategies. Developments in the fields of cognitive neuroscience and 




CI in COPD. Longitudinal studies can pinpoint its determinants and identify its 
consequences, and much work remains to be done in finding (the most) effective 
treatments.
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Background and aims: Cognitive impairment (CI) and metabolic abnormalities, 
including the metabolic syndrome (MetS) and sarcopenia, are more prevalent in 
COPD patients compared to controls without diagnosed lung disease. Because 
earlier studies have shown these metabolic abnormalities may affect cognitive 
performance, this study investigated whether cognitive performance is more 
impaired in subgroups of COPD patients with MetS or sarcopenia.
Methods: Cognitive performance patterns of 170 COPD patients referred 
for pulmonary rehabilitation (53.5% male, 63.4±9.4 years, FEV1 54.5±22.7% 
predicted) were compared between COPD subgroups stratified by presence 
of MetS and sarcopenia. Cognitive performance was assessed using a detailed 
neuropsychological test battery, which measured psychomotor speed (Stroop 
Color-Word Test, Concept Shifting Test, Letter-Digit Substitution Test), planning 
(Behavioral Assessment of the Dysexecutive Syndrome), working memory (Visual-
Verbal Learning Test, Digit Span), verbal memory (Visual-Verbal Learning Test) 
and cognitive flexibility (Stroop Color-Word Test, Concept Shifting Test). MetS was 
determined according to the NCEP ATP-III criteria. Sarcopenia was determined 
based on decreased appendicular lean mass by dual-energy x-ray absorptiometry 
and impaired physical performance by 6-minute walking distance.
Results: MetS was observed in 54.7% and sarcopenia in 30.0% of COPD patients. 
The prevalence of general CI was not different between patients with and without 
MetS (30.4% and 39.0%, respectively) or those with and without sarcopenia (34.0% 
and 34.5%, respectively, both p>0.05). Domain-specific cognitive performance 
was not different between metabolic subgroups, but those with sarcopenia 
displayed a lower prevalence of CI on verbal memory than those without (21.7% 
and 29.7%, respectively, p=0.011). Only the digit span (working memory) subtest 
was significantly different between metabolic subgroups, in favor of those without 
MetS (p=0.017).
Conclusion: Cognitive performance was not affected more in COPD patients with 
sarcopenia or MetS.




Chronic obstructive pulmonary disease (COPD) is often associated with systemic 
manifestations including metabolic syndrome (MetS) and sarcopenia (1, 2). 
Cognitive impairment (CI) is also a common, yet often overlooked, comorbidity 
of COPD, with a recent meta-analysis reporting a 32% prevalence (3). CI in COPD 
has been associated with lower quality of life (4), a higher need for assistance in 
aspects of daily living such as medication adherence and self-management (5) and 
a higher risk of all-cause hospitalization (hazard ratio [HR] for patients with COPD 
and CI compared to controls without COPD and CI 1.34 [95% confidence interval 
1.00-1.80]; HR for patients with COPD but no CI compared to controls without 
either 1.24 [95% confidence interval 1.06-1.45]) (6), and hospitalized patients with 
COPD scored significantly worse on a range of cognitive tests compared to their 
stable counterparts (7). Moreover, patients with CI dropped out of pulmonary 
rehabilitation (PR) twice as often as those without (23.3 versus 10.3%) (8). Although 
the etiology of CI in COPD remains largely unknown, it can be speculated that 
metabolic comorbidities adversely affect cognition in these patients because of 
shared lifestyle-related risks.
MetS is a cluster of cardiovascular risk factors which, according to a recent review, 
affects 34% of patients with COPD, a significantly higher proportion than among 
healthy controls with a comparable body mass index (BMI) (1). MetS is related 
to reduced levels of multiple indices of cerebral (9, 10) and blood-brain barrier 
integrity (11) and a reduced blood oxygenation level-dependent (BOLD) imaging 
signal in frontal and parietal regions (12) in community-dwelling older adults. 
MetS is also associated with impaired working memory and episodic memory 
(13), attention and executive functions (13, 14) in healthy elderly, although one 
study only found significant results in men (13). Some evidence has been found 
for a dose-response relationship, in which a higher number of MetS symptoms 
is associated with worse cognitive performance (13). These effects can be long-
lasting: in one meta-analysis MetS was associated with a decline in cognitive 
performance in participants under 70 years old over a follow-up period of up 
to 16 years (15) and hyperglycemia and insulin resistance have been associated 
with declines in cognitive performance in a community sample over a 20-year 
period between ages 53 and 73 (16). The relative contribution of the separate 
MetS components towards CI remains unclear, although various components or 
combinations thereof with a significant association with CI have been reported, 
such as high-density lipoprotein (HDL) cholesterol (17), hyperglycemia (18), waist 





Sarcopenia is defined as a progressive and generalized skeletal muscle disorder 
that is associated with increased likelihood of adverse outcomes including falls, 
fractures, physical disability and mortality (21). It occurs in normal ageing but is 
more prevalent in COPD (21, 22). In healthy elderly populations, a smaller muscle 
mass has been associated with lower cerebral volume (23) and diminished white 
matter integrity (24) which lead to poorer cognitive performance. Interestingly, 
these cerebral abnormalities have also been shown in COPD (25, 26). Furthermore, 
in healthy elderly, fat-free mass was found to be related to whole-brain volume 
(27) and total lean mass has been associated with whole-brain volume and white 
matter volume (28). In a recent review (29) white matter hyperintensity volume 
and volumes of various brain areas were related to grip strength, but relationships 
with gait speed were much weaker. Some studies have found a two- to threefold 
higher risk of developing CI in healthy participants with low muscle mass (30, 31) 
or functional impairment, defined as a score on the short physical performance 
battery of less than 9 (32). In one smaller sample (N=34) between 71 and 92 years 
old, the risk was even found to be three- to 4.5-fold, depending on the definition 
of sarcopenia (33).
The current study therefore aims to investigate whether the presence of MetS 
or sarcopenia is related to an elevated prevalence and/or different pattern of CI 
in patients with COPD referred for PR. Investigating this putative connection is 




Cognitive performance of 170 patients with COPD referred for PR was compared 
between subgroups stratified by sarcopenia or MetS in a cross-sectional design. 
These patients took part in the COgnitive-PD study (34), which was conducted 
at CIRO, a center of expertise for patients with chronic organ failure in Horn, The 
Netherlands, between November 2013 and June 2015. The study was registered 
in the Dutch Trial Registry (NTR 4215) and approved by the medical ethics 
committee of Maastricht University Medical Center (NL45127.068.13). The 13 
patients who were excluded from the original sample (N=183) had missing data 
on metabolic parameters.




Patients with COPD were eligible to take part in this study if they had a diagnosis 
of COPD based on the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) guidelines (35). Those with clinically unstable COPD in the past 4 weeks, 
a diagnosis of dementia or insufficient mastery of the Dutch language were not 
eligible to participate. All participants gave written informed consent.
The MAAS population was invited from the Registration Network Family Practices, a 
patient register of collaborating general practitioners, representative of the Dutch 
population. Participants were excluded if they suffered from major cerebrovascular 
pathology, a nervous system tumor or congenital malformation, multiple sclerosis, 
Parkinsonism, epilepsy, dementia, organic psychosis, schizophrenia, affective 
psychosis or intellectual disability. Participants with a history of diagnosed lung 
disease were excluded during the matching process. Demographical (age, sex, 
educational level), clinical (BMI) and neuropsychological test data was gathered 
during a 3-hour medical and neurocognitive screening visit. All participants gave 
written informed consent and both studies were conducted in accordance with 
the Helsinki Declaration.
Measurements
Demographics and lung function
Demographics and lung function (flow volumes and diffusion capacity) of the 
patients with COPD were assessed during the 3-day assessment at the start of the 
PR program.
Metabolic risk profile
MetS and sarcopenia parameters were taken in the COPD population from the 
3-day assessment at the start of the PR program. MetS was assessed using the 
National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-
III) criteria (36), and the sample was divided into groups with and without MetS 
based on these cutoffs. Sarcopenia was defined as a combination of low muscle 
mass and functional impairment (21), based on skeletal muscle mass index (SMI) 
and performance on the 6-minute walking test, respectively. SMI was calculated 
as appendicular lean mass (ALM) / height². ALM was determined by dual energy 
x-ray absorptiometry (DEXA). Low muscle mass was defined as an SMI below 7 kg/
m² for men or below 5.5 kg/m² for women, according to Cruz-Jentoft et al. (21). 
Decreased functional performance was defined as a 6-minute walking distance 




al. (37). Participants with low muscle mass and low functional performance based 
on these cut-offs were assigned to the sarcopenia group; those not meeting both 
criteria were assigned to the no-sarcopenia group.
Cognition
Cognitive performance of the patients with COPD was measured using a detailed 
neuropsychological assessment during a home visit prior to starting PR. See 
Cleutjens et al. (34) for details.
General cognitive performance comprised six test scores: the number of animals 
named in the animal naming subtest of the Groninger Intelligence Test-II (38), the 
time to complete card 3 of the Stroop Color-Word Test (39), the time to complete 
part C of the Concept Shifting Test (40), the number of correct items on the Letter-
Digit Substitution Test (41), and the total and delayed recall scores of the Visual-
Verbal Learning Test (42).
Performance on five cognitive domains (psychomotor speed, planning, working 
memory, verbal memory and cognitive flexibility) was assessed using scores on 
the six tests mentioned above, along with the digit span backwards task (43) and 
the Behavioral Assessment of the Dysexecutive Syndrome (BADS) (44). See Table 
1 for a complete overview.
Sample size calculation
The required sample size was based on a power of 80% and an a of 0.05. The 
expected effect size was based on a four-point difference on the St George's 
Respiratory Questionnaire, and a drop-out rate of 10% was taken into account. 
These parameters resulted in a required sample size of 183. Additional details can 
be found in Cleutjens et al. (34). 
Statistical analyses
Statistical analyses were performed using the Statistical Package for the Social 
Sciences (SPSS, IBM Corp., Armonk, NY), version 25. A p-value below 0.05 was 
considered statistically significant.
For cognitive profiling, the patients were individually matched in a 1:1 ratio based 
on age, sex, educational level and BMI to controls from the Maastricht Aging 
Study (45) (MAAS; approved by the local medical ethics committee [MEC-05-
107]). Additional matching on BMI was done because of established independent 
effects on cognitive performance (46) and because BMI is often affected in MetS 
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and sarcopenia. Matching on BMI prevented the effects of BMI-related metabolic 
risk to confound the effects of MetS- and sarcopenia-related metabolic risk.
Individual raw cognitive test scores of the patients with COPD were converted 
into Z-scores using the formula Z = (X — μ) / s, in which X is an individual score, 
μ is the mean of the 170 MAAS participants and s is the standard deviation of 
the 170 MAAS participants (47). Because the BADS and digit span task were not 
Adapted from Cleutjens et al. (34). BADS: Behavioral Assessment of the Dysexecutive Syndrome; 
CST: Concept Shifting Test; LDST: Letter-Digit Substitution Test; SCWT: Stroop Color-Word Test; 
VVLT: Visual-Verbal Learning Test.
Test name Subscore or subtest Parameter measures
Psychomotor speed
SCWT Card I (time in seconds) Reading speed
CST Part A (time in seconds) Simple motor speed
LDST Number of correct items in 60 sec-
onds (written and oral)
Psychomotor speed / informa-
tion processing speed
Planning
BADS Key search (profile score: 0-4) Planning and priority setting
BADS Zoo map (profile score: 0-4)
Working memory
VVLT Trial 1 (number correct: 0-15) Immediate verbal span
Digit span Backward (span: 0-7) Working memory
Verbal memory
VVLT Total recall (number correct: 0-75) Overall verbal learning and 
verbal memory after an interval
Delayed recall (number correct: 0-15)
Retention (percentage of words that 
were retained from the immediate to 
the delayed score)
Cognitive flexibility
SCWT Card III (time in seconds) Attentional inhibition of a dom-
inant response
CST Part C (time in seconds) Alternating attention
Table 1




administered in MAAS, norm values published elsewhere were used (43, 44). 
General CI was defined as a Z-score below -1 on two or more of the six contributing 
tests; domain-specific CI as a Z-score on a specific domain below -1 (47). Domain-
specific cognitive performance scores were obtained by averaging the Z-scores of 
tests belonging to that particular domain.
Within the COPD population, differences on demographic and clinical parameters 
and cognitive performance were assessed between metabolic subgroups using 
independent-samples t-tests or Mann-Whitney U-tests, depending on the 
distribution of the data. The normality of the distribution was determined using the 
Kolmogorov-Smirnov test. Differences on categorical variables and prevalence of 
CI were assessed using c² tests. The influence of smoking status (current/former/
never) and the number of pack years on cognitive performance was assessed 
using analyses of variance and regression analyses, respectively. Smoking status 
and the number of pack years served as independent variables, the separate 
cognitive test scores as dependent variables.
Results
Demographical characteristics are presented in Table 2. The study group consisted 
of 170 patients (53.5% male), aged 63.4±9.4 years, with a BMI of 26.6±5.6 kg/m2 
and moderate to severe airflow obstruction (FEV1 54.5±22.7% predicted). General 
CI was present in 58 patients (34.3%) (see Table 3).
The first trial of the Visual-Verbal Learning Test was the only cognitive test with 
significant differences between current (n=146), former (n=22) and never-smokers 
(n=2), due to a significantly higher score by the never-smokers (p=0.040). Pack 
years were only significantly related to the zoo map test of the BADS (p=0.008) 
and the VVLT delayed recall score (p=0.046).
Metabolic syndrome
The prevalence of MetS was 54.7%. Patients with MetS had a significantly higher 
BMI (p<0.001) and diffusion capacity (p=0.006) than those without. All MetS 
parameters except for systolic and diastolic blood pressure were significantly 
different between the groups, all in the expected directions. ALM, SMI, fat mass 
(all p<0.001) and 6MWD % predicted (p=0.045) were significantly higher in the 
group with MetS compared to that without (see Table 2).
General CI was present in 28 COPD patients with MetS and in 30 without 
(prevalence 30.4% and 39.0%, respectively; p=0.245) (see Table 3). Cognitive 
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domain scores (see Table 4) and the prevalence of domain-specific CI (see 
Figure 1) were not different between the groups with and without MetS. The only 
significant difference between the groups on the separate cognitive subtests was 
a better performance on the digit span backwards test by the group without MetS 
(p=0.017) (see Table 4).
Sarcopenia
The prevalence of sarcopenia was 30.0%. Patients with sarcopenia had a 
significantly lower BMI (p<0.001) and 6MWD than those without, expressed as 
Figure 1





Prevalence of domain-specific CI, divided by sarcopenia status. * p<0.05.
absolute values (p=0.001) and percentage predicted (p<0.001). The distribution of 
current, former and never-smokers was significantly different between the groups, 
with a significantly higher proportion of current and never-smokers in the group 
with sarcopenia (p=0.002). All lung function parameters were significantly higher 
in the group without sarcopenia, indicating better lung function in the patients 
without sarcopenia (all p<0.001), and all MetS and body composition parameters 
except systolic and diastolic blood pressure were significantly different between 
the groups (see Table 2).

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































General CI was present in 17 COPD patients with sarcopenia and in 41 without 
(prevalence 34.0% and 34.5%, respectively; p=0.955) (see Table 3). The prevalence 
of CI on the verbal memory domain was significantly lower in those with sarcopenia 
compared to those without (p=0.011) (see Figure 2), but no cognitive domain 
scores or separate cognitive tests were significantly different between the groups 
(see Table 4).
Discussion
The current study shows a higher prevalence of MetS and sarcopenia in patients 
with COPD eligible for PR, than reported earlier in patients with COPD both in 
and outside of a PR context (1, 48, 49). The prevalence of CI was comparable to 
that in a recent systematic review (3). There was no different pattern of cognitive 
performance in the COPD subgroups with MetS or sarcopenia compared to the 
subgroups without.
MetS and sarcopenia and their separate parameters did not significantly affect 
cognitive performance in our study group. This does not exclude the possibility 
that common and shared lifestyle determinants of metabolic and cognitive 
disturbances in COPD, including physical activity (50, 51) and a low-quality diet 
(52, 53), may explain the high prevalence of impaired cognitive performance. 
Although smoking can also affect cognitive performance (54, 55), its influence 
in the current study was limited. Further research is warranted to disentangle 
the relative contribution of these modifiable lifestyle factors in the etiology and 
progression of CI in COPD.
Our results are at odds with earlier research that did associate MetS (56-58) and 
sarcopenia (59, 60) with poorer cognitive performance in participants without 
COPD. Other studies found non-significant (61-63) or mixed results (17, 18). 
These inconsistent results can result from different sources, such as differences 
in age ranges, in the operationalization of cognitive performance and CI, in 
the operationalization of MetS or sarcopenia or from lack of sufficient power. 
Secondly, methodological weaknesses in cognitive screening can distort results. 
Many previous studies gauged cognition using a single screening tool, which is 
less sensitive than a comprehensive test battery, or excluded participants with 
pre-existing CI (e.g., Mini-Mental State Examination score ≤ 24). The use of a 
screening tool and selectively excluding certain participant groups both reduce 
variance on cognitive outcome measures and could lead to underestimating 
effect sizes. Thirdly, not all of the MetS components are equally strongly associated 
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with cognition (16-18). Also in our sample, only glucose levels were significantly 
positively related to cognition (data not shown).
Strengths of the current study include the use of a comprehensive 
neuropsychological test battery, rather than a single screening tool, to investigate 
cognitive performance. The calculation of Z-scores based on case-control 
matching allowed us to reliably compare cognitive performance of the patient 
population to controls corrected for known determinants of cognitive functioning.
A strength but also potential limitation includes the fact that our study population 
consisted of patients in tertiary care. The prevalence of metabolic derangements 
is high in this population, but many patients have complex pathology and 
comorbidities, which might limit the generalizability of the results to COPD per 
se. Secondly, we were unable to control for confounding factors such as socio-
economic status or COPD disease duration, following the studies by Cleutjens 
et al. (47) and many others. Thirdly, like most other comparable studies, we were 
constrained to a cross-sectional study design, which limits our ability to draw 
conclusions about causality.
In conclusion, COPD subgroups with MetS and sarcopenia exhibited comparable 
patterns of cognitive performance and impairment relative to those without. 
Because earlier research has shown poorer cognitive performance in patients with 
COPD compared to healthy controls, COPD constitutes an indication for cognitive 
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Leading a healthy lifestyle is important for patients with COPD. It benefits their 
overall health status, for instance through slowing down disease progression. 
Nevertheless, the lifestyle of many patients with COPD is unhealthy: some of them 
still smoke, they are often physically inactive (1, 2) and consume an unhealthy diet 
(3-5). This thesis reported that patients' motivational patterns are associated with 
their physical activity and dietary quality, which tentatively indicates that targeted 
motivational counseling might be effective in order to achieve or consolidate 
a healthy lifestyle. However, existing evidence also indicated that improving 
cognitive impairment (CI) or cognitive functioning could be effective to this end. 
Unfortunately, CI remains an under-recognized manifestation of COPD andour 
working memory training (WMT) intervention could not improve overall cognitive 
functioning or adherence to a healthy lifestyle.
This chapter will discuss how the clinical recognition and assessment of CI in COPD 
could be improved, and it will discuss various other potentially effective strategies 
to improve cognitive functioning in patients with COPD and their adherence to a 
healthy lifestyle.
Cognitive impairment as under-recognized COPD 
manifestation
CI is highly prevalent in COPD, with a prevalence of around one in three (6), and 
cognitive performance substantially influences patients’ daily lives. Memory, 
cognitive flexibility and visual processing are related to self-management skills, 
such as the ability to adhere to one’s medication regime (7, 8), and CI in general 
is associated with increased risk for exacerbations and hospitalizations (9-11). 
Nevertheless, many patients and health care professionals under-recognize CI 
as a comorbidity of COPD (12). Even the GOLD guidelines (13), outlining the 
standards in COPD management, do not address cognitive functioning and its 
influence on disease management and daily-life outcomes.
Cognitive screening could be a valuable addition to COPD management, as it 
could enable timely intervention and prevention of the harmful consequences of 
CI. Cognitive screening is not time- or labor-intensive: instruments such as the 
Mini-Mental State Examination (MMSE) (14), the Montreal Cognitive Assessment 
(MoCA) (15) or the Addenbrooke’s Cognitive Examination-Revised (ACE-R) (16) 
take less than ten minutes to administer and are sensitive to detect CI in patients 




values for CI. Moreover, patients with COPD themselves do not regard cognitive 
screening as a strange addition to standard diagnostics (12).
Nurses or lab technicians could periodically conduct this cognitive screening, 
for instance in conjunction with patients’ routine lung function evaluation, which 
usually takes place biannually in The Netherlands. Cognitive screening could be 
followed up in a similar way as spirometric evaluation: if it reveals impairment or 
decline, the general practitioner or chest physician can be informed and advised 
to refer the patient for more comprehensive investigation. Cognitive abnormalities 
could lead, for example, to referral to a memory clinic in the hospital, which can 
administer comprehensive neuropsychological assessment.
Metabolic syndrome and sarcopenia as potential indications for 
screening
Multifactorial involvement of disease-specific determinants, comorbidities and 
unhealthy lifestyle behaviors in the emergence of CI in COPD makes some of 
these factors potentially useful to target screening at specific at-risk subgroups 
of patients with COPD. Metabolic abnormalities such as the metabolic syndrome 
(MetS) and sarcopenia, for instance, are common conditions in patients with COPD 
compared to healthy controls (17, 18) and have been related to the prevalence 
of CI in non-COPD populations (19-23). However, our research showed no 
independent contribution of MetS and sarcopenia towards CI in patients with 
COPD who were referred for pulmonary rehabilitation (PR). This could be specific 
for this COPD subgroup and different in population-based studies. Future research 
is furthermore indicated to identify the potential of other comorbidities or lifestyle 
factors in the risk screening for CI in COPD.
Alternatively, COPD may have a much larger effect on cognitive performance 
than MetS and sarcopenia. The impact of COPD on cognitive functioning might 
therefore overshadow the (perhaps negligible) impact of MetS and sarcopenia. 
This conjecture is supported by the relatively high prevalence of CI in the patients 
who were investigated in our research (almost 40 percent), regardless of MetS 
or sarcopenia status. This prevalence was determined by comparing the patients’ 
cognitive performance to that of non-COPD controls. COPD-general effects on 
cognitive performance could be biologically mediated by accelerated ageing. 
Accelerated biological ageing is a hallmark of COPD (24) and has also been related 
to poorer cognitive performance (25-27) and accelerated cognitive decline (26, 





In case CI is diagnosed, it should ideally be treated, especially in light of the 
serious consequences of CI in patients with COPD. We chose to administer WMT 
as the role of WM underlying general cognition (30) made it a promising target to 
improve overall cognitive performance. However, the results of the Cogtrain trial as 
well as earlier WMT interventions were disappointing. In the Cogtrain trial as well 
as earlier studies, WMT appeared to be able to improve cognitive performance 
on the initially trained tasks, but near transfer (i.e., towards comparable cognitive 
tasks) was scarce and far transfer (i.e., towards unrelated cognitive tasks) was 
virtually non-existent (31-33). To date only one study investigated another type of 
cognitive training in patients with COPD. This intervention, targeting attention and 
logical-deductive thinking with a lower training load than the Cogtrain trial, was 
also ineffective (34).
Based on this evidence, WMT cannot be recommended for use in future studies or 
clinical practice, at least not as a stand-alone intervention in its current form.
Targeting cognitively well- or poorly-performing patients: who 
benefits?
Baseline cognitive performance in the Cogtrain trial was highly variable. The 
median ACE-R score of 88 was relatively poor, but the highest-performing 
quartile of patients showed normal cognitive performance with scores above 94. 
This variability could also explain the non-significant results of the trial, as WMT 
might have different effects on patients with poor and good baseline cognitive 
performance. This has not been investigated in the Cogtrain trial, as the subgroups 
resulting from its relatively small sample size would be too small to draw any 
meaningful conclusions.
On the one hand, cognitively well-performing patients might have diluted effects 
that were present in more poorly-performing ones. Transfer from improved 
performance on one cognitive task towards another is unlikely to occur if 
participants do not improve on the trained tasks (35), and the available room for 
improvement is largest in cognitively poor patients. On the other hand, poorly 
performing patients might also have diluted effects that were present in the 
better ones. Plasticity is a prerequisite for learning and transfer, and it could be 
argued that the potential for cognitive plasticity (i.e., the ability to learn and use 
multiple new cognitive strategies) and neural plasticity (i.e., cerebral physiological 





Improving cognitive functioning does not require standardized or formalized 
cognitive training. Cognitive stimulation associated with daily-life activities such as 
playing chess (36), completing sudokus (37) or even the degree of social contact 
(38, 39) are also associated with improved cognitive functioning. These activities 
have multiple advantages over formalized cognitive training: their structure is less 
rigid and they have a much more ‘gamified’ character, so patients will likely be 
more willing to engage in them and adhere to them. They are easy to incorporate 
into daily life. This increases the likelihood that these activities become a habit, 
which makes it easier to adhere to them in the longer term.
Physical activity, exercise training and the muscle-brain axis
Physical activity and exercise training are among the most effective ways to improve 
brain health and cognitive functioning (40-42). These effects are mediated among 
others by increased cardiac output, social interaction in the case of group exercise 
(43) and extensive muscle-brain crosstalk.
This crosstalk takes place among others through the effects of exercise-induced 
release of myokines such as cathepsin B or FNDC5 (44). These and other 
factors mediate the upregulation of neurotransmitters such as brain-derived 
neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF) and 
insulin growth factor-1 (IGF-1) (44-46). These neurotransmitters improve brain 
health by facilitating neurogenesis, neuronal survival, differentiation, myelination 
and memory formation (43, 47). A large part of these effects takes place in the 
hippocampus (44, 48), which is the primary brain area responsible for memory 
formation.
The kynurenine pathway also plays a key role in this muscle-brain crosstalk. This 
pathway mainly converts tryptophan into kynurenine and further into quinolinic acid 
(an N-methyl-D-aspartate receptor [NMDAR] agonist which induces excitotoxicity 
in the brain) or kynurenic acid (an NMDAR antagonist with neuroprotective 
properties) (49, 50). Quinolinic and kynurenic acid cannot cross the blood-
brain barrier, but kynurenine can (51). Kynurenine should therefore ideally be 
metabolized in the periphery, to prevent it from crossing the blood-brain barrier 
and being metabolized into neurotoxic compounds in the central nervous system. 
This risk is especially present in patients with COPD, because inflammation, which 
is systemically heightened in patients with COPD (13), promotes the conversion 




kynurenine-to-tryptophan ratio (KTR) has been negatively related to cognitive 
performance (52).
Exercise promotes peripheral kynurenine metabolism (and therefore potentially 
benefits cognitive performance) through increasing PGC-1a and PPARa/d 
expression in the skeletal muscle (53). This leads to increased skeletal muscle 
kynurenine aminotransferase (KAT) expression (49, 53), which in turn promotes 
the conversion of kynurenine into kynurenic acid (53). Indeed, the peripheral KTR 
of healthy young adults was significantly lower 1 hour after exercise compared 
to baseline (49). Indirectly improving cognitive performance in COPD via such 
exercise-induced muscular improvements makes sense in theory, as their plasma 
kynurenine levels are significantly higher than those of healthy controls and their 
skeletal muscle KAT expression is significantly lower (54).
Nutritional supplementation, dietary management and the gut-brain 
axis
Brain health and cognitive performance may also be improved by targeting the 
gut microbiome. The gut microbiome communicates with the brain through the 
‘gut-brain axis’ (55). This axis consists of many different pathways. It releases pro- 
and anti-inflammatory cytokines such as interleukin-1 and -6, which modulate the 
activity of the hypothalamic-pituitary-adrenal gland (HPA) axis (55). It secretes 
short-chain fatty acids which activate microglial cells that have anti-inflammatory 
effects in the brain (56). It modulates the activity of the vagus nerve, which is 
associated with improved cognitive functioning in the general population when 
it is done exogenously (57, 58), and it also regulates the levels of (precursors of) 
important neurotransmitters such as serotonin, gamma aminobutyric acid (GABA), 
noradrenalin, dopamine and acetylcholine (55, 56).
The composition of the gut microbiome and the functioning of the gut-brain axis 
can be improved by administering so-called ‘psychobiotics’. Psychobiotics are 
“pre- and probiotics that, ingested in appropriate quantities, have a positive mental 
health benefit” (55). Fructooligosaccharides (FOS) and galactooligosaccharides 
(GOS), for instance, stimulate the growth of intrinsic commensal microbiota, which 
are bacteria in the gut that positively influence the diversity of the gut microbiome 
(55). The current evidence for the beneficial effects of psychobiotics is strongest 
for stress, anxiety and depression (59); surprisingly, there is a paucity of research 
into the effects of psychobiotic supplementation on cognitive performance. 
Future studies may therefore further investigate this topic, and whether and how 





Various nutrients can also modulate the gut microbiome and gut-brain axis. 
The NUTRECOVER trial, which is currently ongoing within the department of 
respiratory medicine at Maastricht University, will unravel the effects of a nutritional 
supplement containing tryptophan, vitamin D, omega-3 polyunsaturated fatty 
acids (PUFA) and prebiotic fibers on among others cognitive performance in 
patients with COPD who have been hospitalized with an acute exacerbation.  This 
‘cocktail’ may simultaneously moderate the kynurenine pathway and the gut-
brain axis. The anti-inflammatory properties of PUFAs, such as eicosapentaenoic 
acid (EPA) or docosahexaenoic acid (DHA) (60), could shift the metabolism of 
the supplemented tryptophan and subsequently kynurenine in the brain towards 
kynurenic acid instead of quinolinic acid. Additionally, the prebiotic fibers may 
improve the composition of the gut microbiome (59), which might in turn also 
benefit the kynurenine pathway (61). Clinical trials have already shown positive 
effects of PUFA and dietary fiber supplementation on cognitive performance in 
cognitively healthy elderly and those with mild CI (62-64). A lower vitamin D status 
has been associated with poorer cognitive performance in (older) adults without 
dementia, although the benefits of supplementing it are still unclear (65). 
Consuming a healthy diet, such as the Mediterranean diet (66-70), a prudent diet 
(71), the Dietary Approaches to Stop Hypertension (DASH) diet (69, 70) and the 
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet (70), 
can also improve cognitive performance. The Mediterranean diet and the prudent 
diet are characterized by high fruit, vegetable, fish, wholegrain, oil, legume, 
nut and low-fat dairy intake while limiting the intake of red meat, sweets, sugar-
containing beverages, fat and cholesterol (69, 71). The DASH diet is largely similar 
but places a larger emphasis on low-fat dairy and low dietary sodium intake and 
alcohol abstinence (69), whereas the MIND diet combines the Mediterranean and 
DASH diets and emphasizes plant-based foods over animal foods and foods high 
in saturated fat (70).
Nootropics
Nootropics are pharmacological substances that can be used to enhance cognitive 
performance, such as (ar)modafinil and methylphenidate, but also caffeine or 
nicotine (72-74). They are popular in the general population (mainly among 
students in order to enhance their academic performance). Taking nootropics is a 
much easier way to enhance cognitive performance compared to strategies such 
as exercise or consuming a healthy diet, but it is associated with considerable 
drawbacks. Firstly, substances such as methylphenidate or modafinil (primarily 
indicated in The Netherlands for attention deficit / hyperactivity disorder and for 




enhancement in mind. As such, the evidence base for their cognitive performance-
enhancing properties is weak, especially in people with comparable demographical 
and pathophysiological characteristics as typical patients with COPD. Most meta-
analyses and systematic reviews have investigated their effects in younger adults 
or in patients with traumatic brain injury (77, 78). Secondly, nootropics can have 
unintended and undesirable side effects such as headaches or insomnia (75, 76). 
Thirdly, they should be very carefully administered as overdosing can lead to 
suboptimal cognitive performance (79) and harmful effects on cerebral functioning 
(80). Therefore, using nootropics with the sole aim of cognitive enhancement (i.e., 
without any other indication) cannot be recommended.
One class of medication that might be feasible as a nootropic in patients with 
COPD are phosphodiesterase (PDE)-4 inhibitors such as roflumilast. They have 
been shown to improve cognitive performance in animal models of Alzheimer's 
disease (81) and chronic cerebral hypoperfusion (82). Acute administration 
of 100μg (but not 250, 300, 500 or 1000μg) roflumilast significantly improved 
immediate recall memory performance in healthy young adults (83) and delayed 
recall memory performance in healthy older adults (84).
Roflumilast has recently been indicated in The Netherlands to treat patients with 
severe COPD (FEV1 < 50% predicted) who suffer from frequent exacerbations 
despite optimal triple therapy (85). Its potential to simultaneously improve the 
health status and cognitive functioning of patients with COPD would make it a 
promising intervention. Moreover, it is relatively cheap, with an estimated price per 
day of €1.74 (85). However, although acute administration of the recommended 
therapeutic dose for COPD (500μg) tended to lead to better cognitive performance 
compared to placebo in participants without COPD, these differences were not 
significant (83, 84). The effects of long-term roflumilast administration on human 
cognitive performance have not been investigated to our knowledge. Hence, 
whether roflumilast administration alone or as part of standard COPD management 
could contribute to cognitive improvement remains to be investigated.
Pulmonary rehabilitation
PR is also prescribed to patients with severe COPD as part of standard disease 
management (86). PR includes many components with proven benefits on 
cognitive performance, such as exercise training and nutritional support (86), and 
the available evidence indeed provides tentative indications of favorable effects 
of PR on cognitive performance (43, 87-89). The necessary investment in terms 
of money, time and effort do not make PR a viable option to improve cognitive 




patients who are referred for PR based on the existing indications. Moreover, 
the likely poor cost-effectiveness of PR to improve cognitive functioning does 
not negate the fact that incorporating its key elements, such as physical activity, 
exercise and dietary improvement, into daily life will likely benefit cognitive 
performance, as discussed above. Future research should expand on the existing 
evidence base with methodologically stronger studies. They should for instance, 
in contrast to earlier studies, include a non-PR control group (43, 87) and include 
a broader sample of patients than only certain subsets such as those who have 
undergone a lung transplantation (89).
PR is a very effective intervention to improve health outcomes, but its transfer 
into an actual healthier lifestyle after completion of the program and after the 
associated support and structure are taken away, is only poor (90). Interventions 
targeting patients’ daily lives in the first place may be more effective.
Comprehensive lifestyle interventions
Many modifiable lifestyle factors influence cognitive performance. The Dutch 
Alzheimer Centre lists mental and physical inactivity, smoking, depression, 
overweight, hypertension and diabetes as important risk factors to develop 
dementia (91). Targeting one factor in an intervention while leaving all others 
constant therefore likely only has a small effect on cognitive performance. Instead, 
interventions likely become more effective as more factors are targeted.
However, in spite of this enhanced effectiveness in theory, the current empirical 
evidence for such multidomain interventions is mixed. Over the past decade, three 
large-scale studies have investigated the potential of comprehensive lifestyle 
interventions to diminish the risk of developing dementia: the Finnish Geriatric 
Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) (92), 
the preDIVA study (93) and the Multidomain Alzheimer Preventive Trial (MAPT) 
(94). The 2-year FINGER strategy consisted of nutritional management, exercise 
training, cognitive training and vascular risk monitoring. The 6-year preDIVA 
study combined usual cardiovascular care with tailored lifestyle advice based 
on motivational interviewing principles; the 3-year MAPT trial offered cognitive 
training, physical activity, nutritional supplementation and educational sessions. 
The FINGER trial was able to prevent cognitive decline to a significantly greater 
degree than general health advice, but the preDIVA and MAPT studies did not 
lead to significant changes in cognitive decline compared to placebo groups. In 
conclusion, there is a clear need for future studies to investigate the potential of 





Working memory training and adherence to a healthy lifestyle
In this thesis WMT was hypothesized to be able to contribute to a healthier lifestyle 
through its ability to increase cognitive control (95, 96). This would enable patients 
to inhibit automatic responses in favor of more opportune controlled ones (97). 
However, the Cogtrain trial showed no effects of WMT on adherence to a healthy 
lifestyle, the recall of prespecified healthy lifestyle goals or motivation towards a 
healthy lifestyle.
One potential explanation for these non-significant results is that transfer from 
improved performance on one cognitive domain to other cognitive domains is 
already scarce (31, 32). Transfer towards healthy lifestyle outcomes would have to 
reach even further. All of these outcomes are determined by a potentially endless 
number of pathways involving motivational, environmental (e.g., the weather, social 
support, financial issues) and health-related factors (e.g., disease progression). 
WMT-induced improved cognitive control may contribute to adherence to a 
healthy lifestyle, but it is not a panacea.
Secondly, the positive effects of earlier studies investigating the effects of WMT on 
healthy lifestyle outcomes or stress susceptibility were largely found on lab-based 
parameters or tasks (such as a bogus taste test in participants with overweight or 
metabolic parameters in those with type 2 diabetes) instead of actual healthier 
lifestyles (i.e., weight loss or disease management) (95, 98). Even studies which 
selectively included specific subgroups of participants who stood to gain a lot 
by participating, such as people with overweight in studies with weight loss as 
a primary outcome (99) or heavy drinkers in a study aiming to reduce substance 
abuse (100), were largely ineffective. The one recent study investigating the effects 
of WMT on stress responses found positive results on the biological response to 
stress (measured by cortisol levels) but did not include a measure of subjective 
stress perception (101).
Thirdly, increasing cognitive control might not be necessary or sufficient to 
establish a healthy lifestyle. It might not be sufficient because a large proportion 
of patients with COPD appear not to know what is and is not healthy: 30% of 
them qualify as being health illiterate (102, 103). Future studies and clinical efforts 
may therefore have to add educational components in order to enable patients to 
keep the right information in mind. However, the effectiveness of combining only 
WMT and education is doubtful (95), implying that these components will also 




Combining education, WMT and additional interventional components is a highly 
cumbersome way to achieve a healthier lifestyle. All of this might not be necessary 
in the first place, because it could simply and effectively be bypassed using a 
technique called ‘nudging’ (104). . Nudging consists of altering certain aspects 
of people’s environment with the aim of automatically guiding them towards a 
certain choice even though they retain the freedom to choose any number of 
other options (104). It therefore minimizes the necessary involvement of cognitive 
control, instead of maximizing its capacity. Nudging can be very easy and subtle, 
and it can unconsciously change behavior: it can consist of placing the fruit and 
vegetables department immediately at the entrance of a supermarket and making 
it impossible not to pass through it before reaching other departments with 
unhealthier items. Importantly, customers retain full freedom to pick unhealthy 
products, but the likelihood of them buying fruit and vegetables is much larger 
compared to when the fruit and vegetables department is located in the middle or 
the back of the store. Its non-coercive nature also makes nudging much more likely 
to be effective, also in the longer term, compared to educational or prescriptive 
approaches telling you what you ‘should’ or ‘should not’ do (105, 106).
General conclusion
CI is an important comorbidity of COPD, which should be better recognized and 
dealt with in the clinic. WMT as single intervention does not improve cognitive 
performance in COPD. Future initiatives to improve cognitive performance 
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Chronic obstructive pulmonary disease (COPD) is a high-burden chronic respiratory 
disease. It is currently the third most common cause of death worldwide, with an 
estimated 3 million deaths in 2016. Traditional interventions to improve the health 
status of patients with COPD, such as supervised pulmonary rehabilitation (PR) 
programs, are effective in the short term but often do not translate into a healthier 
and generally more active lifestyle after completion of the program. Promising 
additional or alternative approaches to maintain or improve health status of COPD 
patients include motivational counseling towards a healthy lifestyle, targeted 
nutritional intervention or working memory training (WMT).
Cognitive impairment (CI) is a common extrapulmonary manifestation of COPD, 
and is evidenced for example by memory loss or reduced speed of thinking. CI is 
a problem in itself, but also affects overall health status of patients with COPD and 
may influence their ability to adhere to a healthy lifestyle. 
The main aim of this thesis was therefore to investigate determinants of cognitive 
performance in patients with COPD and the potential efficacy of WMT next to 
motivational regulations in increasing patients’ adherence to a healthy lifestyle.
Chapter 2 reports the long-term results of the randomized, placebo-controlled 
NUTRAIN trial. This study investigated the cost-effectiveness of a nutritional 
management strategy in patients with COPD and low muscle mass (often referred 
to as sarcopenia). The strategy consisted of targeted nutritional supplementation 
(leucine, polyunsaturated fatty acids and vitamin D) in a medical drink and dietary 
counselling during a 4-month outpatient PR program and a subsequent 8-month 
maintenance phase. Relative to usual care (PR without follow-up intervention) 
physical capacity increased in both groups, but the nutritional management 
approach ameliorated plasma levels of the supplemented nutrients, prevented 
unintended weight loss, and positively influenced daily physical activity and 
generic health.
Chapter 3 investigates whether motivational regulations are related to healthy 
lifestyle behaviors (physical activity and adherence to a healthy diet) and the 
responsiveness thereof after an outpatient PR program. Levels of identified 
motivation (i.e., performing an action because it is valued as personally important 
to someone) predicted dietary quality change during PR and its levels after PR; 
levels of introjected motivation (i.e., performing an action out of fear of the shame 
associated with not doing it) predicted change in physical activity levels during PR 




Chapter 4 provides a narrative review of the initial knowledge base around 
CI in COPD. Based on the current literature, several disease-specific factors, 
comorbidities and unhealthy lifestyle factors may contribute to the emergence 
of CI in COPD, which affects around one in three patients. A diffuse pattern of 
cognitive domains is affected, in contrast to disease-specific patterns such as the 
selective loss of memory (but not other cognitive domains) in Alzheimer’s disease. 
These impairments have a detrimental impact on patients’ self-management 
abilities, health outcomes, ability to engage in activities of daily living and quality 
of life, while increasing their hospitalization risk.
Chapter 5 investigates whether the presence of the metabolic syndrome or 
sarcopenia is related to an elevated prevalence and/or different pattern of CI 
in patients with COPD referred for PR. These conditions are more common in 
COPD than in healthy controls and adversely affect health status and survival. 
COPD patients with one of these comorbidities might be especially vulnerable to 
develop CI, as these conditions have been independently associated with poor 
cognitive functioning in non-COPD populations. In the studied COPD population 
referred for PR, the prevalence of metabolic syndrome (54.7%) and sarcopenia 
(30.0%) was high, but not associated with a higher prevalence of CI.
Chapter 6 reports the results of the randomized, placebo-controlled Cogtrain trial. 
In this trial a 12-week home-based working memory training (WMT) program was 
administered, followed by a 12-week maintenance program. The efficacy of WMT 
to establish and maintain improvements in cognitive performance, adherence to a 
healthy lifestyle and cognitive stress susceptibility was investigated in patients with 
COPD. Although the intervention improved performance on the actual (working 
memory) tasks that were used for training, these improvements did not generalize 
to other cognitive performance domains. The WMT did not improve adherence 
to a healthy lifestyle or cognitive stress susceptibility either. These results indicate 
that WMT is not an effective way to improve cognitive performance and potentially 
related healthy lifestyle behavior in patients with COPD.
Chapter 7 positions the results of the current thesis in a broader scientific and 
clinical perspective, with particular emphasis on cognitive functioning in COPD 
and on the potential efficacy of interventions to improve cognitive performance 
and adherence to a healthy lifestyle in patients with COPD.
The overall results of the current thesis indicate that CI is an important comorbidity 
of COPD, which should be better recognized and dealt with in clinical care. CI 
has an independent substantial detrimental impact on daily-life functioning 




metabolic syndrome and sarcopenia) do not appear to be useful screening factors 
for CI in patients with COPD. WMT did not improve cognitive functioning or 
adherence to a healthy lifestyle. However, motivational regulations were shown to 








COPD is een veelvoorkomende en ernstige chronische longziekte, die momenteel 
de op twee na meest voorkomende doodsoorzaak wereldwijd is. In 2016 was 
COPD naar schatting verantwoordelijk voor 3 miljoen doden. Gangbare niet-
medicamenteuze interventies om de algemene gezondheid van patiënten met 
COPD te verbeteren, zoals longrevalidatie, zijn effectief op korte termijn, maar 
beklijven vaak niet op de langere termijn via een gezondere leefstijl. Een gerichte 
voedingsaanpak, motivationele counseling en werkgeheugentraining zijn 
veelbelovende aanvullende of alternatieve behandelingen om de gezondheid en 
leefstijl van patiënten met COPD te verbeteren.
Verminderd cognitief functioneren, zoals bijvoorbeeld geheugenverlies of een 
vertraagd denkvermogen, komt vaak voor bij COPD. Deze cognitieve beperkingen 
beïnvloeden de algehele gezondheid van patiënten met COPD en verminderen 
hun vermogen om gezond te leven.
In deze thesis is nader onderzoek verricht naar de risicofactoren voor cognitief 
functieverlies bij COPD alsmede de trainbaarheid van het cognitief functioneren 
middels werkgeheugentraining. Daarnaast is onderzocht of deze training naast 
een doelgerichte voedingsinterventie en inzicht in verschillende vormen van 
motivatie kan bijdragen aan een gezondere leefstijl van patiënten met COPD.
Hoofdstuk 2 rapporteert de langetermijnsresultaten van de gerandomiseerde, 
placebo-gecontroleerde NUTRAIN-trial. De interventiegroep ontving een 
medische drinkvoeding die verrijkt was met leucine, meervoudig onverzadigde 
vetzuren en vitamine D gedurende een 4 maanden durend poliklinisch 
revalidatieprogramma en counseling middels motivationele interviews tijdens de 
daaropvolgende onderhoudsfase van 8 maanden. Deze interventie verbeterde 
na 12 maanden de plasmaniveaus van de gesuppleerde nutriënten, voorkwam 
gewichtsverlies en verminderingen in fysieke activiteit en algemene gezondheid, 
en was kosteneffectief. Een verbeterde fysieke capaciteit na de longrevalidatie 
bleef behouden voor zowel de interventiegroep als de controlegroep.
Hoofdstuk 3 onderzoekt of verschillende vormen van motivatie voor het naleven 
van een gezonde leefstijl daadwerkelijk gerelateerd zijn aan een gezonde leefstijl 
(fysieke activiteit en een gezond dieet) tijdens en na afloop van een poliklinisch 
longrevalidatieprogramma. Dit werd onderzocht in het kader van de NUTRAIN 
trial. Niveaus van geïdentificeerde motivatie (m.a.w. een actie uitvoeren omdat die 
aansluit bij iemands persoonlijke waarden) waren gerelateerd aan de verandering 
in de kwaliteit van het dagelijkse voedingspatroon tijdens en na afloop van 
longrevalidatie; niveaus van geïntrojecteerde motivatie (het uitvoeren van een 




waren gerelateerd aan de verandering in fysieke activiteit tijdens en na afloop van 
de revalidatie.
Hoofdstuk 4 betreft een narratieve review over de bestaande literatuur over 
verminderd cognitief functioneren in patiënten met COPD. Dit hoofdstuk toont 
aan dat enkele ziekte-specifieke factoren, comorbiditeiten en een ongezonde 
leefstijl kunnen bijdragen tot het ontstaan van cognitieve beperkingen in COPD. 
Deze beperkingen treffen ongeveer een op de drie patiënten. Veel verschillende 
cognitieve domeinen kunnen aangedaan worden maar er bestaat geen ziekte-
specifiek patroon zoals het geheugenverlies dat karakteristiek is voor de vroege 
stadia van de ziekte van Alzheimer. Cognitieve beperkingen hebben een negatief 
effect op de gezondheid, het vermogen tot zelfmanagement, het dagelijks 
leven en de kwaliteit van leven van patiënten met COPD. Bovendien verhogen 
cognitieve beperkingen het risico op een ziekenhuisopname.
Voortbouwend op deze review is in Hoofdstuk 5 onderzocht of de aanwezigheid 
van het metabool syndroom of sarcopenie gerelateerd is aan een hogere 
prevalentie en/of een verschillend patroon van cognitieve beperkingen in 
patiënten met COPD die verwezen waren voor longrevalidatie. Deze metabole 
aandoeningen komen vaker voor in COPD dan in gezonde controles, en we weten 
uit eerder onderzoek dat beide metabole condities op zichzelf geassocieerd 
zijn met een verminderd cognitief functioneren. Het metabool syndroom en 
sarcopenie hadden een hoge prevalentie in onze bestudeerde COPD-populatie 
(respectievelijk 54.7% en 30.0%), maar ze bleken niet gerelateerd te zijn aan een 
hogere prevalentie van cognitieve beperkingen. Dit zijn daarom geen bruikbare 
indicaties voor aanvullende cognitieve screening.
Hoofdstuk 6 toont de resultaten van de gerandomiseerde, placebo-gecontroleerde 
Cogtrain-trial. Dit onderzoek bestond uit een 12-weekse werkgeheugentraining, 
gevolgd door een 12-weeks onderhoudsprogramma, in patiënten met COPD. 
Het doel van het onderzoek was om verbeteringen te bewerkstelligen en te 
consolideren in het cognitief functioneren, de leefstijl en de vatbaarheid voor 
cognitieve stress. Hoewel het functioneren op de getrainde (werkgeheugen-)taken 
duidelijk verbeterde, waren er geen verbeteringen te zien op andere cognitieve 
domeinen na de training. De interventie had ook geen effecten op de andere 
onderzochte parameters. Werkgeheugentraining lijkt dus geen effectieve manier 
om het cognitief functioneren en daarmee samenhangende leefstijlaspecten van 
patiënten met COPD te verbeteren.
Hoofdstuk 7 plaatst de resultaten van het onderzoek in een breder 




om het cognitief functioneren en een bestendige gezondere leefstijl te verbeteren 







Chronic obstructive pulmonary disease (COPD) is one of the highest-burden 
chronic diseases worldwide. Lung function impairment is characterized by 
airflow limitation that is usually progressive and largely irreversible (1). COPD 
is a substantial cause of disability and mortality: 299 million people worldwide 
were estimated to suffer from the disease in 2017 and COPD was responsible 
for 3 million deaths in 2016, making it the third most common cause of death 
worldwide (2).
Although COPD is primarily a lung disease, various manifestations outside the 
respiratory system are common, including metabolic abnormalities (3, 4), muscle 
dysfunction (5) and cognitive impairment (CI) (6). CI worsens patients' quality 
of life (7, 8) and health outcomes (9, 10), it decreases their ability to engage in 
activities of daily living (11) and it increases their risk of hospitalization (12). All 
of this contributes to a vicious cycle in which patients' health status deteriorates 
even further, and to a considerable economic burden for society (13, 14). It is 
therefore very important to optimally manage COPD from a holistic perspective, 
consider CI as comorbidity and to assist patients in attaining and maintaining a 
healthy lifestyle. This thesis investigated determinants of cognitive performance 
in patients with COPD and the potential efficacy of working memory training 
(WMT) and nutritional management next to motivational regulations in increasing 
patients' adherence to a healthier lifestyle.
Relevance for patients
The results of this thesis are very relevant to patients with COPD. Awareness 
regarding the adverse impact of their disease and leads for improvement might 
translate into their health status and wellbeing. Improved prospective memory 
could for example improve self-management and treatment adherence. Improved 
executive functioning could enhance self-control, enabling patients to resist 
tempting unhealthy lifestyle choices in favor of more controlled and healthier 
ones. The WMT that we developed and evaluated as single intervention was 
unable to improve overall cognitive functioning or adherence to a healthy lifestyle. 
Nevertheless, interventional modalities, such as daily-life cognitive stimulation 
(e.g., playing chess (15), completing sudokus (16) or engaging in social interaction 
(17, 18)) physical activity (19, 20) and dietary improvement (21, 22), have been 
shown to benefit cognitive performance in non-COPD populations and are 




Relevance for clinical practice
Raising awareness for cognitive impairment in COPD and interventions (also) 
targeting cognitive functioning in these patients is very relevant for caregivers. 
The prevalence of CI was particularly high in patients referred for pulmonary 
rehabilitation (PR) compared to earlier prevalence estimates in stable patients 
in population studies (6). This, and the fact that CI has been related to adverse 
health outcomes including the likelihood of dropping out of PR (23), underlines 
the importance for PR providers to recognize the possible presence of CI in their 
patients and to tailor educational programs to patients’ cognitive capacities.
Furthermore, new insights in specific motivational regulations associated with 
indicators of adherence to a healthy lifestyle (i.e., physical activity and dietary 
quality) are important to consider in refining COPD-specific lifestyle counseling 
interventions.
Relevance for society
A main aim of this thesis was to determine the health and lifestyle benefits of 
the investigated interventions. WMT was ineffective, but targeted nutritional 
management improved patients’ health status at an increase of costs that might 
be considered acceptable for patients with a high disease burden. Moreover, 
motivational interventions, if proven feasible as discussed above, might cost-
effectively improve patients’ lifestyle, health status, quality of life and functional 
capacities as well. This enables patients to live more meaningful lives for a longer 
period of time, for instance by prolonging their ability to work. Furthermore, it 
might decrease health care expenditure and the COPD-associated disability 
burden. Both are relevant for society, as rising health care costs present a large 
and growing economic burden and COPD is the fifth-leading cause of disability-
adjusted life years (DALYs) worldwide (24).
Relevance for commercial parties
Motivational counselling does not have to remain confined to health care 
professionals. In fact, counselling by commercial parties would take work away 
from health care professionals, which would alleviate the growing work pressure 




Incorporating counselling into an e-health application could reduce the workload 
associated with counselling even further. Various applications have been developed 
over the past years to improve chronic disease management with promising 
results on health outcomes, such as myIBDcoach (25, 26) for inflammatory bowel 
disease and SanaCoach COPD for COPD (27). Counselling could even take place 
entirely virtually. Habtic, an app developed to improve the lifestyle of corporate 
employees, already uses such virtual, yet highly realistic, avatars.
The NUTRAIN trial showed that nutritional supplementation can improve the 
overall health status of patients with COPD in a cost-effective manner. Further 
developing medical foods and/or supplements, aimed at improving physical 
capacity and health status but also building forth upon promising results regarding 
their benefits on cognitive functioning (28, 29), for instance, could therefore be 
promising for commercial parties.
Developing WMT modalities and marketing them as games has been an important 
focus of industry in the past 20 years. Although these games are often supported 
by claims that their effectiveness has been proven, independent investigations 
routinely indicate they do not improve cognitive or real-life task performance (30-
32). The results of the current thesis  also indicate that further developing WMT 





1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the 
Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 
Agusti A, Vogelmeier C, editors; 2020.
2. World Health Organization. The top 10 causes of death 2018 [accessed July 16, 2020]. 
Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-
of-death.
3. Trajanoska K, Schoufour JD, Darweesh SKL, Benz E, Medina-Gomez C, Alferink LJM, 
et al. Sarcopenia and its clinical correlates in the general population: the Rotterdam 
Study. Journal of Bone and Mineral Research. 2018;33(7):1209-18.
4. Cebron Lipovec N, Beijers RJ, Van den Borst B, Doehner W, Lainscak M, Schols AMWJ. 
The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: a 
systematic review. COPD. 2016;13(3):399-406.
5. Remels AH, Gosker HR, Langen RC, Schols AMWJ. The mechanisms of cachexia 
underlying muscle dysfunction in COPD. Journal of Applied Physiology. 
2013;114(9):1253-62.
6. Yohannes AM, Chen W, Moga AM, Leroi I, Connolly MJ. Cognitive impairment in 
chronic obstructive pulmonary disease and chronic heart failure: a systematic review 
and meta-analysis of observational studies. JAMDA. 2017;18:451.e1-.e11.
7. Dodd JW, Charlton RA, Van den Broek MD, Jones PW. Cognitive dysfunction in patients 
hospitalized with acute exacerbation of COPD. Chest. 2013;144(1):119-27.
8. Roncero C, Campuzano AI, Quintano JA, Molina J, Perez J, Miravitlles M. Cognitive 
status among patients with chronic obstructive pulmonary disease. International 
Journal of COPD. 2016;11:543-51.
9. Brega AG, Grigsby J, Kooken R, Hamman RF, Baxter J. The impact of executive 
cognitive functioning on rates of smoking cessation in the San Luis Valley Health and 
Aging Study. Age and Ageing. 2008;37(5):521-5.
10. Meek P, Lareau SC, Anderson D. Memory for symptoms in COPD patients: how accurate 
are their reports? European Respiratory Journal. 2001;18(3):474-81.
11. Baird C, Lovell J, Johnson M, Shiell K, Ibrahim JE. The impact of cognitive impariment 
on self-management in chronic obstructive pulmonary disease: a systematic review. 
Respiratory Medicine. 2017;129:130-9.
12. Chang SS, Chen S, McAvay GJ, Tinetti ME. Effect of coexisting chronic obstructive 
pulmonary disease and cognitive impairment on health outcomes in older adults. 
Journal of the American Geriatric Society. 2012;60(10):1839-46.
13. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, 





14. Mannino DM, Higuchi K, Yu T-C, Zhou H, Li Y, Tian H, et al. Economic burden of COPD 
in the presence of comorbidities. Chest. 2015;148(1):138-50.
15. Lillo-Crespo M, Forner-Ruiz M, Riquelme-Galindo J, Ruiz-Fernández D, García-
Sanjuan S. Chess practice as a protective factor in dementia. International Journal of 
Environmental Research and Public Health. 2019;16(12):2116.
16. Ferreira N, Owen A, Mohan A, Corbett A, Ballard C. Associations between cognitively 
stimulating leisure activities, cognitive function and age-related cognitive decline. 
International Journal of Geriatric Psychiatry. 2015;30(4):422-30.
17. Kelly ME, Duff H, Kelly S, McHugh Power JE, Brennan S, Lawlor BA, et al. The impact 
of social activities, social networks, social support and social relationships on the 
cognitive functioning of healthy older adults: a systematic review. Systematic Reviews. 
2017;6:259.
18. Biddle KD, D’Oleire Uquillas F, Jacobs HIL, Zide B, Kirn DR, Rentz DM, et al. Social 
engagement and amyloid-b-related cognitive decline in cognitively normal older 
adults. American Journal of Geriatric Psychiatry. 2019;27(11):1247-56.
19. Falck RS, Davis JC, Best JR, Crockett RA, Liu-Ambrose T. Impact of exercise training on 
physical and cognitive function among older adults: a systematic review and meta-
analysis. Neurobiology of Aging. 2019;79:119-30.
20. Song D, Yu DSF, Li PWC, Lei Y. The effectiveness of physical exercise on cognitive and 
psychological outcomes in individuals with mild cognitive impairment: a systematic 
review and meta-analysis. International Journal of Nursing Studies. 2018;79:155-64.
21. Martínez-Lapiscina EH, Clavero P, Toledo E, Estruch R, Salas-Salvadó J, San Julián B, 
et al. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised 
trial. Journal of Neurology, Neurosurgery and Psychiatry. 2013;84(12):1318-25.
22. Van den Brink AC, Brouwer-Brolsma EM, Berendsen AAM, Van de Rest O. The 
Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and Mediterranean-
DASH Intervention for Neurodegenerative Delay (MIND) diets are associated with 
less cognitive decline and a lower risk of Alzheimer’s disease - a review. Advances in 
Nutrition. 2019;10(6):1040-65.
23. Cleutjens FAHM, Spruit MA, Ponds RWHM, Vanfleteren LEGW, Franssen FM, Dijkstra 
JB, et al. The impact of cognitive impairment on efficacy of pulmonary rehabilitation in 
patients with COPD. JAMDA. 2017;18(5):420-6.
24. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, 
and national incidence, prevalence, and years lived with disability for 354 diseases 
and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the 




25. De Jong M, Van der Meulen-De Jong A, Romberg-Camps M, Becx M, Maljaars JP, Cilissen 
M, et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): 
a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390(10098):959-
68.
26. De Jong M, Van der Meulen-De Jong A, Romberg-Camps M, Degens J, Becx M, Markus 
T, et al. Development and feasibility study of a telemedicine tool for all patients with 
IBD: MyIBDcoach. Inflammatory Bowel Disease. 2017;23(4):485-93.
27. Trappenburg J, Niesink A, De Weert-Van Oene GH, Van der Zeijden H, Van Snippenburg 
R, Peters A, et al. Effects of telemonitoring in patients with chronic obstructive 
pulmonary disease. Telemedicine Journal and E-Health. 2008;14(2):138-46.
28. Külzow N, Witte AV, Kerti L, Grittner U, Schuchardt JP, Hahn A, et al. Impact of omega-3 
fatty acid supplementation on memory functions in healthy older adults. Journal of 
Alzheimer’s disease. 2016;51(3):713-25.
29. Troesch B, Eggersdorfer M, Laviano A, Rolland Y, Smith AD, Warnke I, et al. Expert 
opinion on benefits of long-chain omega-3 fatty acids (DHA and EPA) in aging and 
clinical nutrition. Nutrients. 2020;12(9):2555.
30. Etherton JL, Oberle CD, Rhoton J, Ney A. Effects of Cogmed working memory training 
on cognitive performance. Psychological Research. 2019;83(7):1506-18.
31. Harris DJ, Wilson MR, Vine SJ. A systematic review of commercial cognitive training 
devices: implications for use in sport. Frontiers in Psychology. 2018;9:709.
32. Kable JW, Caulfield MK, Falcone M, McConnell M, Bernardo L, Parthasarathi T, et al. No 
effect of commercial cognitive training on brain activity, choice behavior, or cognitive 






Ik zie mezelf nog bij Juul in de tuin staan op het moment dat ik een promotieplek 
in Leuven aangeboden kreeg. Die positie zei ik af, ik ging weer een paar maanden 
in de supermarkt werken, en daarop kreeg ik te horen "dat ik drie jaar zonder 
baan zou zitten" en ik "er nooit meer tussen zou komen". Inmiddels kunnen we 
denk ik stellen dat die conclusies enigszins voorbarig waren.
Mijn masterscriptiebegeleidster vatte in haar dankwoord haar promotietraject 
samen in één uitspraak. "Het was vaak fantastisch en soms verschrikkelijk". 
Dat wil ik graag volmondig beamen. Het was fantastisch wanneer gezellige 
proefpersonen langskwamen voor meetdagen, wanneer ik borrels en symposia 
organiseerde met mijn 'vriendenteam' van de aio-raad, of wanneer ik me staande 
hield presenterend in een zaal vol professoren op een groot congres. Het was 
verschrikkelijk op de nachten waarop ik om vijf uur wakker werd, alles voor me 
zag wat fout kon gaan met mijn onderzoek, en vervolgens vier wakkere uren later 
met kleine oogjes achter mijn bureau schoof. Hierbij wil ik graag de belangrijkste 
mensen bedanken die er de afgelopen vier jaar bij waren.
Annemie, ik ben ontzettend dankbaar voor de kans die je me gaf om te 
promoveren. Het was echt niet vanzelfsprekend om deze promotieplek te geven 
aan een 22-jarig jochie zonder enige achtergrond in longziekten. Ik heb altijd 
ontzettend veel bewondering gehad voor het gruwelijk hoge niveau waarop je 
denkt en heb enorm genoten van de mogelijkheid om daarvan te leren. Ik moet 
je bij tijden gek gemaakt hebben met al mijn vlaaipunten, maar ik hoop dat deze 
promotie je vertrouwen in me terugbetaalt.
Harry, jouw bijdrage aan mijn promotietraject wordt perfect belichaamd door je 
reddingsactie op de Maas, toen jij en Ramon de banter boat met mij en Justine 
naar het eindpunt gidsten. Drive en enthousiasme heb ik altijd genoeg gehad, 
maar aan richting ontbrak het wel eens, en die richting heb je zowel op de Maas 
als in mijn promotietraject verzorgd. Bedankt voor alle keren dat je me wees op 
dingen die ik niet handig aanpakte, dat je me terechtwees als ik om de zaken 
heen draaide als ze niet gingen zoals ze moesten gaan - en uiteraard voor die 
reddingsactie op de Maas.
Zonder al mijn proefpersonen was dit proefschrift er natuurlijk ook niet geweest. 
U heeft de moeite genomen om een aantal tientallen uren van uw leven naar 
een computerschermpje te turen, bijna de helft van u zelfs in de placebogroep. 
Hoewel het niet altijd even leuk was (dat heb ik van sommigen van u wel begrepen), 
hoop ik dat de gezelligheid tijdens de afspraken op de universiteit daar wat 
voor gecompenseerd heeft. Het patiëntencontact is voor mij in ieder geval erg 




beetje een idee te krijgen van wat er achter de woorden en statistieken in dit 
boekje zit.
Mijn kamergenoten waren in meerdere opzichten mijn reddingsboei. Stephanie 
in het prille begin bij MRI-meetdagen en METC-aanvragen, en om me met zachte 
hand wat realisme in te praten als mijn planning weer eens wat te optimistisch 
bleek. Ik heb het je in de afgelopen jaren al vaker gezegd, maar wat moet ik je bij 
tijden tot wanhoop hebben gedreven. Lisanne als grote ondersteuning binnen 
Cogtrain en om me er regelmatig aan te herinneren dat ik soms eens wat minder 
slordig moest zijn. En Vasili: kamergenoot, vriend, paranimf, slapie, drinkmaatje, 
wingman, relatie-adviseur, en degene die binnen no-time een straalkacheltje 
geregeld kreeg als de verwarming er thuis weer eens mee ophield. Reddingsboei 
doet de beschrijving van je rol tekort.
Er komt natuurlijk maar één andere persoon in aanmerking om mijn paranimf 
te zijn. Viv, wij zijn er al jaren altijd voor elkaar, niet in het minst tijdens onze 
wandelingetjes door Heugem en De Heeg, of tijdens onze dinertjes. Bij mij 
thuis, in Huize Mimosa of sinds kort in Helden-Panningen. Ik ben enorm trots op 
je, super blij dat je zo goed op je plek zit, en ik hoop nog vele foto's met foute 
Snapchat-filters met je te kunnen maken.
De collega's met wie ik ontelbare koffietjes, lunches, dinertjes in het personeels-
restaurant en avonden clubpower gedeeld heb, in het bijzonder Inez, Ellen, 
Denise, Philippe, Timme, Justine en Sara.
Mijn collega's van de aio-raad: Annet, Charlotte, Elisa, Eva, George, Gianluca, 
Heike, Jacco, Kelly, Mattea, Mirjam, Pauline en Sara.
Mijn andere huidige en voormalige collega's van pulmonologie: Anita, Ardy, 
Bregtje, Caspar, Cheryl, Chiel, Coby, Judith, Jules, Juliette, Lieke, Karin, Marco, 
Mieke, Niki, Pieter, Ramon, Rianne, Rosanne, Sara(h), Sophie, Viviënne, Wessel, 
Wouter G en Wouter v/d W.
Hurra, hurra, die V2E ist auch noch da! Hangry buien in Gent, het monster van 
Toth in Antwerpen, de grote triomfen en diepe dalen van ons voetbalcluppie die 
we door het hele land heen hebben gezien: jullie zijn al bijna vijftien jaar lang een 
constante factor. Het feit dat ik de eerste maar zeker niet de laatste promovendus 
van ons groepje ben is hopelijk het ultieme bewijs van onze VWO+-mentaliteit . . .
Pa, voor alle PSV-gerelateerde hoogte- en dieptepunten die we de afgelopen 
twintig jaar hebben gedeeld. Tien jaar lang op vak UU, rij 37, stoel 47; 




een beetje kan kanaliseren, en dat we 't dan ten minste eens zijn over dat iemand 
als Pablo Rosario niet bij een club als PSV in de basis hoort.
En als laatste natuurlijk de belangrijkste vrouwen in mijn leven. Fré, omdat 
je er altijd, altijd voor me bent. Ik kan niet wachten om met je samen te gaan 
wonen en samen een mooie toekomst (verder) op te bouwen. Juul, voor de 
driekwartliterflessen La Chouffe die we leeg hebben getutterd, en mamma - 
misschien dat ik wel het meeste zeg als ik zeg dat jouw bijdrage aan mijn promotie 
en mijn ontwikkeling in het algemeen niet in een dankwoord te beschrijven 
is. Wie weet waar ik was geweest zonder jouw hulp en advies, en zonder onze 
wandelrondjes langs het kanaal. In ieder geval niet hier in de positie waarin ik je 
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